June 2008

CURRICULUM VITAE

THOMAS N. WIGHT, Ph.D.

Benaroya Research Institute at Virginia Mason
Hope Heart Program
1201 Ninth Avenue
Seattle, Washington 98101-2795
Phone: (206) 341-1377
Fax: (206) 341-1370
Email: twight@benaroyaresearch.org

RESEARCH INTERESTS

The cell biology and pathology of connective tissue. Specific interests include cell-extracellular matrix interactions with emphasis on the role of proteoglycans and associated molecules in the regulation of cell behavior.

EDUCATION

Ph.D.	1972	University of New Hampshire, Durham, New Hampshire; Zoology
M.S.	1968	University of New Hampshire, Durham, New Hampshire; Zoology
B.A.	1966	University of Maine, Orono, Maine; Zoology

POSTGRADUATE TRAINING

1972 - 1974	NIH Postdoctoral Fellow, University of Washington, Seattle, Washington

FACULTY POSITIONS HELD

2008 - present	Director, Hope Heart Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington
2007 - present	Affiliate Faculty, Diabetes & Obesity Center of Excellence, School of Medicine, University of Washington, Seattle, Washington
2004 - present	Member, Hope Heart Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington
2000 - 2004	Chair, Vascular Biology, The Hope Heart Institute, Seattle, Washington
2000 - present	Affiliate Professor of Pathology, Department of Pathology, School of Medicine, University of Washington, Seattle, Washington
1988 - 2000	Professor of Pathology, Department of Pathology, School of Medicine, University of Washington, Seattle, Washington
1983 - 1988	Associate Professor of Pathology, Department of Pathology, School of Medicine, University of Washington, Seattle, Washington
1978 - 1983	Assistant Professor of Pathology, Department of Pathology, School of Medicine, University of Washington, Seattle, Washington
1974 - 1978	Assistant Professor of Animal Science, Director of Electron Microscopy, University of New Hampshire, Durham, New Hampshire

HONORS

2007 - Present	Elected Trustee, International Society of Hyaluronan Sciences (ISHAS)
2006 - Present	Elected Council Member, Histochemical Society
2005 - Present	Elected Council Member, American Society of Matrix Biology
1990 - Present	Fellow, American Heart Association (FAHA)
1981 - 1986	Established Investigator, American Heart Association
1972 - 1974	National Institute of Health Postdoctoral Fellowship
1972	Phi Sigma Outstanding Graduate Student Award
1970 - 1972	New Hampshire Heart Association Predoctoral Fellowship
1966 - 1970	National Defense Education Act Predoctoral Fellowship

PROFESSIONAL MEMBERSHIPS

American Association for the Advancement of Science
American Association of Pathologists
Fellow, American Heart Association (Council on Arteriosclerosis)
The Histochemical Society
American Society for Matrix Biology
American Society for Investigative Pathology

SPECIAL NATIONAL RESPONSIBILITIES

2007 - 2008	Chair, Proteoglycans, 2008 Gordon Research Conference
2006 - present	Program Committee for the Annual Meeting of the American Heart Association
2005 - present	Board Member, The Hope Heart Institute
2005 - present	Editorial Board: *Matrix Biology*
2005 - present	Editorial Board: *Current Cardiology Reviews*
2004 - present	Editorial Board: *Arteriosclerosis, Thrombosis, and Vascular Biology*
1998 - present	Editorial Board (Associate Editor): *Journal of Histochemistry and Cytochemistry*
2001	Member, Board of Scientific Counselors, Craniofacial and Skeletal Diseases Branch (NIDCR, NIH)
1999 - 2003	Study Section Member for Research Awards, American Heart Association
1998 - 2001	Editorial Board: *Arteriosclerosis, Thrombosis and Vascular Biology*
1994 - 2000	Editorial Board: *Glycoconjugate Journal*
1990 - 2001	Editorial Board: *Archives of Biochemistry and Biophysics*
1986 - 1989	Pathobiochemistry Study Section (Regular Member)
1982 - 1986	Ad Hoc Member of Pathobiochemistry Study Section, NIH

SPECIAL NATIONAL RESPONSIBILITIES - continued

1980 - present	Ad Hoc Reviewer National Science Foundation, Veterans Administration
1978 - present	Ad Hoc Reviewer (minimum of 5 papers/year) *American Journal of Pathology*; *Atherosclerosis*; *Biochemistry*; *Circulation; Circulation Research*; *Journal of Biological Chemistry*

DEPARTMENT AND UNIVERSITY RESPONSIBILITIES

1997 - 2000	Appointments and Promotion Committee, School of Medicine, UW
1991 - 1993	Associate Director, Interdisciplinary Molecular and Cellular Biology Program, UW
1990 - 2000	Appointments and Promotion Committee, Department of Pathology, UW
1986 - 1992	Cell Biology Training Program Planning Committee, UW
1986 - 1990	Executive Subcommittee of the Admissions Committee, UW
1983 - 1991	Co-Director, Graduate Program, Department of Pathology, UW
1983 - 1990	Admissions Committee, School of Medicine, UW
1978 - 1987	Director, Electron Microscopy Laboratory, UW School of Medicine

TEACHING EXPERIENCE

University of Washington

2006 - present	Lecturer - "Atherosclerosis and Myocardial Infarction," Path 511
1984 - present	Lecturer - "Human Pathology" Path 444
1983 - present	Lecturer - Graduate Student Proseminar, Path 501
1978 - present	Supervisor - Medical students, undergraduates, graduate students Research Lab rotations, Path 551
1978 - present	Served on 5 Master of Science Thesis Committees, 23 Doctoral Thesis Committees, currently supervising two graduate students
1993 - 1999	Lecturer - "Molecular and Cell Biology" Conjoint 503
1991 - 1994	Course Director / Lecturer - Molecular and Cell Biology" Conjoint 503,504,505
1991 - 1994	Course Director - Graduate Student Seminar "Molecular and Cell Biology" Conjoint 514, 515
1991	Preceptor - Health Science Minority Students Research Apprentice Program

University of New Hampshire

1974 - 1978	Course Director / Lecturer	Advanced Cell Biology
1974 - 1978	Course Director / Lecturer	Introduction to Electron Microscopy

CURRENT RESEARCH AWARDS **Annual Direct Costs**
(does not include F & A)

2006 - 2011	Biology of the Artery Wall and Atherosclerosis NIH / NHLBI (J. Harlan, PI) "Pro-inflammatory ECM: Key roles for Hyaluronan & Versican" Project 5, Principal Investigator	$248,950
2006 - 2011	Bioengineered Allogeneic Tissue (BEAT) NIH / NHLBI (B. Ratner, PI) Lead Investigator	$100,805
2004 - 2009	Regulation of Cell Function by Matricellular Hevin NIH/NCI (T. Wight)	$197,634
2006 - 2009	Matricellular Protein-regulated Macrophage Recruitment $60,000 *via* Stabilin-1 and VEGF Receptor 1 AHA (T. Wight)	
2004 - 2010	Human Lipoprotein Pathophysiology (LPPG) NIH / NHLBI Program Project (J. Albers, PI) "Lipoprotein Proteogylcans Interaction" Project 4, Co-Investigator	$25,448
2006 - 2008 $22,500	Micro-thickness Collagen Membranes in Tissue Engineering NIH / NIBIB (R. Vernon, PI) Co-Investigator, 15% effort	
2008 - 2010	Engineered Tissue Replacement Parts DOD (M. Allen, PI) "Engineered Tissue Replacement Parts" Major Project 2, Principal Investigator	$130,354
2008 - 2009	Retention of Inflammatory Leukocytes by the Extracellular Matrix (ECM) in Asthma: Alterations in Response to the (R)- and S-Isomers of Albuterol Sepracor (T. Wight, Co-PI)	$90,000
2007 - 2009	The use of a Mouse Model of HGPS to Define the Influence of Lamin AΔ50 Expression on Vascular Extracellular Matrix Production and the Development of Vascular Disease Progeria Research Foundation (T. Wight, PI)	$30,000

Current Total Annual Direct Costs: $940,121

PUBLICATIONS

1. Santerre RF, **Wight TN**, Smith SC, Brannigan D. Spontaneous atherosclerosis in pigeons: A model system for studying metabolic parameters associated with atherogenesis. *Am J Pathol* 67:1-22, 1972. PMID: 4261591

2. **Wight TN**, Ross R. Proteoglycans in primate arteries. I. Ultrastructural localization and distribution in the intima. *J Cell Biol* 67:660-674, 1975. PMID: 53234

3. **Wight TN**, Ross R. Proteoglycans in primate arteries. II. Synthesis and secretion of glycosaminoglycans by smooth muscle cells in culture. *J Cell Biol* 67:675-686, 1975. PMID: 127802

4. **Wight TN**. Synthesis and secretion of glycosaminoglycans by primate arterial smooth muscle cells in vitro. In: *The Smooth Muscle of the Artery*, Wolfe S, Werthessen NT, eds, Plenum Press, *Adv Exp Med Bio*l 57:103-110, 1975.

5. **Wight TN**, Cooke PH, Smith SC. An electron microscopic study of pigeon aorta cell cultures. Cytodifferentiation and intracellular lipid accumulation. *Exp Mol Pathol* 27:1-18, 1977. PMID: 885216

6. Perry LL, **Wight TN**, Collins WM, Dunlop WR. Differentiation of progressive *versus* regressive Rous virus-induced avian sarcomas according to tumor and infiltrating lymphocyte fine structure. *Poultry Sci* 57:80-84, 1978. PMID: 209431

7. Gallagher ET, Harris N, Morin P, Wight TN. Effects of carrageenan on chick embryo fibroblasts *in vitro* – A preliminary study. In: *Scanning Electron Microscopy, vol. II*, Becker RP, Johari D, eds, SEM Inc., Chicago, 779-784, 1978.

8. Levine H, **Wight T**, Squires E. Ultrastructure of the corpus luteum of the cycling mare. *Biol Reprod* 20:492-504, 1979. PMID: 572235

9. Hajjar DP, **Wight TN**, Smith SC. Lipid accumulation and ultrastructural change within the aortic wall during early spontaneous atherogenesis. *Am J Pathol* 100:683-705, 1980. PMID: 7416236

10. **Wight TN**. Differences in the synthesis and secretion of sulfate glycosaminoglycans by aorta explant monolayers cultured from atherosclerosis-susceptible and -resistant pigeons. *Am J Pathol* 101:127-42, 1980. PMID: 7446697

11. **Wight TN**. Vessel proteoglycans and thrombogenesis. In: *Progress in Hemostasis and Thyrombosis*, *vol 5*, Spaet T, ed, Grune and Stratton Inc., New York, pp. 1-39, 1980. PMID: 7422873

12. Iozzo RV, Goldes JA, Chen WJ, **Wight TN**. Glycosaminoglycans of pleural mesothelioma: A possible biochemical variant containing chondroitin sulfate. *Cancer* 48:89-97, 1981. PMID: 6786728

13. Verdery RB, Nist C, Fijimoto WY, **Wight TN**, Glomset JA. Reversible ultrastructural changes in human fibroblasts grown in hapes buffered MCDB-104 supplemented with human serum. *In Vitro* 17:956-964, 1981. PMID: 6274787

14. **Wight TN**. Proteoglycans and atherosclerosis. In: *Diabetes and Atherosclerosis Connection,* Moskowitz J, ed, Juvenile Diabetes Foundation Medical Services Press, 1981.

PUBLICATIONS - continued

15. Oohira A, **Wight TN**, McPherson J, Bornstein P. Biochemical and ultrastructural studies of proteoheparan sulfates synthesized by PYS-2, a basement membrane-producing cell line. *J Cell Biol* 92:357-367, 1982. PMID: 6174529

16. Iozzo RV, Kushwaha RS, **Wight TN**, Hazzard WR. Cellular and subcellular distribution of ^{125}I-labeled very low density lipoproteins in the liver of normal and estrogen-treated rabbits. *Am J Pathol* 107:6-15, 1982. PMID: 6950667

17. Iozzo RV, MacDonald GH, **Wight TN**. Immunoelectron microscopic localization of catalase in human eosinophilic leukocytes. *J Histochem Cytochem* 30:697-701, 1982. PMID: 6809811

18. Schmidt RA, Glomset JA, **Wight TN**, Habenicht AJ, Ross R. A study of the influence of mevalonic acid and its metabolites on the morphology of swiss 3T3 cells. *J Cell Biol* 95:144-153, 1982. PMID: 7142283

19. Iozzo RV, Bolender RP, **Wight TN**. Proteoglycan changes in the intercellular matrix of human colon carcinoma: an integrated biochemical and stereological analysis. *Lab Invest* 47:124-138, 1982. PMID: 7109538 *(This paper received the Benjamin Castleman Award for Outstanding paper in the field of human pathology.)*

20. Iozzo RV, **Wight TN**. Isolation and characterization of proteoglycans synthesized by human colon and colon carcinoma. *J Biol Chem* 257:11135-11144, 1982. PMID: 7107648

21. Iozzo RV, Marroquin R, **Wight TN**. Analysis of proteoglycans by high-performance liquid chromatography: a rapid micromethod for the separation of proteoglycans from tissue and cell culture. *Anal Biochem* 126:190-199, 1982. PMID: 7181110

22. **Wight TN**, Hascall VC. Proteoglycans in primate arteries. III. Characterization of the proteoglycans synthesized by arterial smooth muscle cells in culture. *J Cell Biol* 96:167-176, 1983. PMID: 6402516

23. Oohira A, **Wight TN**, Bornstein P. Sulfated proteoglycans synthesized by vascular endothelial cells in culture. *J Biol Chem* 258:2014-2021, 1983. PMID: 6337150

24. Martin GM, Ogburn CE, **Wight TN**. Comparative rates of decline in the primary cloning efficiencies of smooth muscle cells from the aging thoracic aorta of two murine species of contrasting maximum lifespan potentials. *Am J Pathol* 110:236-245, 1983. PMID: 6401930

25. Harris-Hooker SA, Gajdusek CM, **Wight TN**, Schwartz SM. Neovascular responses induced by cultured aortic endothelial cells. *J Cell Physiol* 114:302-310, 1983. PMID: 6187756

26. Chang Y, Yanagishita M, Hascall VC, **Wight TN**. Proteoglycans synthesized by smooth muscle cells derived from monkey (*Macaca nemestrina*) aorta. *J Biol Chem* 258:5679-5688, 1983. PMID: 6406504

27. **Wight TN**, Curwen KD, Litrenta MM, Alonso DR, Minick CR. Effect of endothelium on glycosaminoglycan accumulation in injured rabbit aorta. *Am J Pathol* 113:156-164, 1983. PMID: 6638149

PUBLICATIONS - continued

28. Ross R, **Wight TN**, Strandess E, Thiele B. Human atherosclerosis – I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. *Am J Pathol* 114:79-93, 1984. PMID: 6691417

29. Cliff WJ, **Wight TN**. Microvessels in avian atheroma. In: *Progress in Microcirculation Research II.* Courtice FC, Garlick DG, Perry MA, eds, Committee in Postgraduate Medical Education, University of New South Wales, Sydney, pp. 205-209, 1984.

30. Chen K, **Wight T**. Proteoglycans in arterial smooth muscle cell cultures: an ultrastructural histochemical analysis. *J Histochem Cytochem* 32:347-357, 1984. PMID: 6200530

31. Clowes AJ, Clowes MM, Gown AM, **Wight TN**. Localization of a proteoheparan sulfate in rat aorta. *Histochemistry* 80:379-384, 1984. PMID: 6234265

32. **Wight TN**, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. *J Histochem Cytochem* 33:295-302, 1985. PMID: 3884704

33. Bingel SA, Sande RD, **Wight TN**. Chondrodysplasia in the Alaskan malamute: characterization of proteoglycans dissociatively extracted from dwarf growth plates. *Lab Invest* 53:479-485, 1985. PMID: 4046558

34. **Wight TN**. Proteoglycans in pathological conditions: atherosclerosis. *Fed Proc* 44:381-385, 1985. PMID: 3881292

35. Singer JW, Keating A, **Wight TN**. The human haematopoietic microenvironment. *Recent Adv Haematol* 4:1-24, 1985.

36. **Wight TN**, Kinsella MG, Potter-Perigo S. Proteoglycans synthesized and secreted by cultured vascular cells. In: *Extracellular Matrix: Structure and Function*, Reddi AH, ed, *J Cell Biochem*, 26:S8B, Alan Liss, NY, pp. 321-322, 1985.

37. Bryant E, Salk D, **Wight T**. Proteoglycans in the Werner Syndrome and aging: a review and perspective. *Adv Exp Med Biol* 190:553-565, 1985. PMID: 3909769

38. **Wight TN**, Kinsella MG, Lark MW, Potter-Perigo S. Vascular cell proteoglycans: Evidence for metabolic modulation. *Ciba Found Symp* 124:241-259, 1986. PMID: 3816418

39. **Wight TN**, Kinsella MG, Keating A, Singer JW. Proteoglycans in human long-term bone marrow cultures: biochemical and ultrastructural analyses. *Blood* 67:1333-1343, 1986. PMID: 2421806

40. Kinsella MG, **Wight TN**. Modulation of sulfated proteoglycan synthesis by bovine aortic endothelial cells during migration. *J Cell Biol* 102:679-687, 1986. PMID: 3081523

41. Bingel SA, Sande RD, **Wight TN**. Undersulfated chondroitin sulfate in cartilage from a miniature poodle with spondyloepiphyseal dysplasia. *Connect Tissue Res* 15:283-302, 1986. PMID: 2946551

42. Garrigues HJ, Lark MW, Lara S, Hellström I, Hellström KE, **Wight TN**. The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface. *J Cell Biol* 103:1699-1710, 1986. PMID: 2430975

PUBLICATIONS - continued

43. Kapoor R, Phelps CF, **Wight TN**. Physical properties of chondroitin sulfate/dermatan sulfate proteoglycans from bovine aorta. *Biochem J* 240:575-583, 1986. PMID: 3814097

44. Lark M, **Wight TN**. Modulation of proteoglycan metabolism by aortic smooth muscle cells grown on collagen gels. *Arteriosclerosis* 6:638-650, 1986. PMID: 3778308

45. Mar H, Tsukada T, Gown AM, **Wight TN**, Baskin DG. Correlative light and electron microscopic immunocytochemistry on the same section with colloidal gold. *J Histochem Cytochem* 35:419-425, 1987. PMID: 3546488

46. Charbord P, Tippens D, **Wight TN**, Gown AM, Singer JW. Stromal cells from human long-term marrow cultures, but not cultured marrow fibroblasts, phagocytose horse serum constituents: studies with a monoclonal antibody that reacts with a species-specific epitope common to multiple horse serum proteins. *Exp Hematol* 15:72-77, 1987. PMID: 3780891

47. Singer JW, Charbord P, Keating A, Nemunaitis J, Raugi G, **Wight TN**, Lopez JA, Roth GJ, Dow LW, Fialkow PJ. Simian virus 40-transformed adherent cells from human long-term marrow cultures: cloned cell lines produce cells with stromal and hematopoietic characteristics. *Blood* 70:464-474, 1987. PMID: 3038214

48. Carlson SS, **Wight TN**. Nerve terminal anchorage protein 1(TAP-1) is a chondroitin sulfate proteoglycan: biochemical and electron microscopic characterization. *J Cell Biol* 105:3075-3086, 1987. PMID: 3693407

49. **Wight TN**, Lark MW, Kinsella MG. Blood vessel proteoglycans. In: *The Biology of the Extracellular Matrix*, Wight TN, Mecham RP, eds, Academic Press, NY, pp. 267-300, 1987.

50. **Wight TN**. Extracellular matrix changes in atherosclerosis. In: *Diseases of the Arterial Wall*, Camilleri JP, Berry CL, Fiessinger JN, Bariety J, eds, Medicine Sciences Flammarion, Paris, pp 163-173, 1987.

51. Kinsella MG, **Wight TN**. Structural characterization of heparan sulfate proteoglycan subclasses isolated from bovine aortic endothelial cell cultures. *Biochemistry* 27:2136-2144, 1988. PMID: 2967719

52. Sandell LJ, Sawhney RS, Yeo TK, Poole AR, Rosenberg LC, Kresse H, **Wight TN**. Cell-free translation of mRNA encoding an arterial smooth muscle proteoglycan core protein. *Eur J Cell Biol* 46:253-258, 1988. PMID: 3139412

53. Lark MW, Yeo TK, Mar H, Lara S, Hellström I, Hellström KE, **Wight TN**. Arterial chondroitin sulfate proteoglycan: localization with a monoclonal antibody. *J Histochem Cytochem* 36:1211-1221, 1988. PMID: 3047228

54. Mar H, **Wight TN**. Colloidal gold immunostaining on deplasticized ultra-thin sections. *J Histochem Cytochem* 36:1387-1395, 1988. PMID: 2844888

55. Kinsella MG, **Wight TN**. Isolation and characterization of dermatan sulfate proteoglycans synthesized by cultured bovine aortic endothelial cells. *J Biol Chem* 263:19222-19231, 1988. PMID: 3198623

PUBLICATIONS - continued

56. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, **Wight TN**. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. *Am J Pathol* 133:456-463, 1988. PMID: 2974240

57. Mar H, **Wight TN**. Correlative light and electron microscopic immunocytochemistry in pre-embedded resin sections with colloidal gold. In: *Colloidal Gold: Principles, Methods, & Applications, vol II*, Hayat MA, ed, Academic Press, Orlando, FL, 1989.

58. Wechezak AR, **Wight TN**, Viggers RF, Sauvage LR. Endothelial adherence under shear stress is dependent upon microfilament reorganization. *J Cell Physiol* 139:136-146, 1989. PMID: 2708451

59. **Wight TN**, Potter-Perigo S, Aulinskas T. Proteoglycans and vascular cell proliferation. *Am Rev Respir Dis* 140:1132-1135, 1989. PMID: 2508521

60. Snow AD, Lara S, Nochlin D, **Wight TN**. Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. *Acta Neuropathol (Berl)* 78:113-123, 1989. PMID: 2473592

61. Swedberg SH, Brown BG, Sigley R, **Wight TN**, Gordon D, Nichols SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. clinical, immunocytochemical, light and electron microscopic assessment. *Circulation* 80:1726-1736, 1989. PMID: 2688974

62. Snow AD, Mar H, Nochlin D, **Wight TN**. Congo red staining on 1 micron de-plasticized sections for detection of lesions in Alzheimer's disease and related disorders. *Prog Clin Biol Res* 317:383-91, 1989. PMID: 2690107

63. **Wight TN**. The cell biology of arterial proteoglycans. *Arteriosclerosis* 9:1-20, 1989. PMID: 2643420

64. Snow AD, **Wight TN**. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. *Neurobiol Aging* 10:481-497, 1989. PMID: 2682326

65. Juul S, Ledbetter D, **Wight TN**, Woodrum D. New insights into idiopathic infantile arterial calcinosis. Three patient reports. *Am J Dis Child* 144:229-233, 1990. PMID: 2405640

66. Snow AD, Bolender RP, **Wight TN**, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. *Am J Pathol* 137:313-330, 1990. PMID: 2386199

67. Kinsella MG, **Wight TN**. Formation of high molecular weight of dermatan sulfate proteoglycan in bovine aortic endothelial cell cultures: evidence for transglutaminase-catalyzed cross-linking to fibronectin. *J Biol Chem* 265:17891-17898, 1990. PMID: 1976631

68. Snow AD, **Wight TN**, Nochlin D, Koike Y, Kimata K, DeArmond SJ, Prusiner SB. Immunolocation of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. *Lab Invest* 63:601-611, 1990. PMID: 1977959

PUBLICATIONS - continued

69. Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, **Wight TN**. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. *Am J Pathol* 137:1253-1270, 1990. PMID: 2146882

70. Levy BJ, **Wight TN**. Structural changes in the aging submucosa: new morphologic criteria for evaluation of the unstable human bladder. *J Urol* 144:1044-1055, 1990. PMID: 2398553

71. Schönherr E, Järveläinen HT, Sandell LJ, **Wight TN**. Effects of platelet-derived growth factor and transforming growth factor-β1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. *J Biol Chem* 266:17640-17647, 1991. PMID: 1894644

72. Järveläinen HT, Kinsella MG, **Wight TN**, Sandell LJ. Differential expression of small chondroitin/dermatan sulfate proteoglycans PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. *J Biol Chem* 266:23274-23281, 1991. PMID: 1744124

73. Snow AD, Bramson R, Mar H, **Wight TN**, Kisilevsky R. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. *J Histochem Cytochem* 39:1321-1330, 1991. PMID: 1940305

74. Juul SE, **Wight TN**, Hascall VC. Proteoglycans. In: *The Lung, Scientific Foundations, vol I*, Crystal RC, West JB, eds, Raven Press, NY, pp. 413-420, 1991.

75. **Wight TN**. Dynamic interactions of proteoglycans. In: *Atherosclerosis: Cellular and Molecular Interactions in the Artery Wall*, Gotlieb AI, Langille BL, Fedoroff S, eds, Plenum Press, pp. 115-125, 1991.

76. **Wight TN**. Proteoglycans. In: *Encyclopedia of Human Biology, vol 6*, Dulbecco R, ed, Academic Press, NY, 1991.

77. **Wight TN**, Heinegard DK, Hascall VC. Proteolgycans: structure and function. In: *Cell Biology of Extracellular Matrix*, Hay ED, ed, Plenum Press, pp. 45-78, 1991.

78. Hascall VC, Heinegard DK, **Wight TN**. Proteoglycans: metabolism and pathology. In: *Cell Biology of Extracellular Matrix*, Hay ED, ed, Plenum Press, pp. 149-175, 1991.

79. Snow AD, Mar H, Nochlin D, Kresse H, **Wight TN**. Peripheral distribution of dermatan sulfate proteolgycans (decorin) in amyloid-containing plaques and their presence in neruofibrillary tangles of Alzheimer's disease. *J Histochem Cytochem* 40:105-113, 1992. PMID: 1370306

80. Yeo TK, MacFarlane S, **Wight TN**. Characterization of a chondroitin sulfate proteoglycan synthesized by monkey arterial smooth muscle cells *in vitro*. *Connect Tiss Res* 27:265-277, 1992. PMID: 1374303

81. Potter-Perigo S, Braun KR, Schönherr E, **Wight TN**. Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from β-D-xyloside inhibition of proliferation. *Arch Biochem Biophys* 297:101-109, 1992. PMID: 1637172

PUBLICATIONS - continued

82. Qwarnström, EE, Kinsella MG, MacFarlane SA, Page RC, **Wight TN**. Modulation of proteoglycan metabolism by human fibroblasts maintained in an endogenous three-dimensional matrix. *Eur J Cell Biol* 57:101-108, 1992. PMID: 1639087

83. Yeo TK, Yeo KT, **Wight TN**. Differential transport kinetics of chondroitin sulfate and dermatan sulfate proteoglycan by monkey aorta smooth muscle cells. *Arch Biochem Biophys* 294:9-16, 1992. PMID: 1550362

84. Fukuchi K, Deeb SS, Kamino K, Ogburn CE, Snow AD, Sekiguchi RT, **Wight TN**, Piussan H, Martin GM. Increased expression of β-amyloid protein precursor and microtubule-associated protein τ during the differentiation of murine embryonal carcinoma cells. *J Neurochem* 58:1863-1873, 1992. PMID: 1560239

85. Järveläinen HT, Iruela-Arispe ML, Kinsella MG, Sandell LJ, Sage EH, **Wight TN**. Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis *in vitro*. *Exp Cell Res* 203:395-401, 1992. PMID: 1281110

86. **Wight TN**, Kinsella MG, Qwarnström EE. The role of proteoglycans in cell adhesion, migration and proliferation. *Curr Opin Cell Biol* 4:793-801, 1992. PMID: 1419056

87. Juul SE, Kinsella MG, **Wight TN**, Hodson WA. Alterations in nonhuman primate (*M. nemestrina*) lung proteoglycans during normal development and acute hyaline membrane disease. *Am J Resp Cell Mol Biol* 8:299-310, 1993. PMID: 8448019

88. Schönherr E, Järveläinen HT, Kinsella MG, Sandell LJ, **Wight TN**. Platelet-derived growth factor and transforming growth factor-β_1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. *Arterioscler Thromb* 13:1026-1036, 1993. PMID: 8318504

89. Potter-Perigo S, Prather P, Baker C, Altman LC, **Wight TN**. Partial characterization of proteoglycans synthesized by human gingival epithelial cells in culture. *J Periodontal Res* 28:81-91, 1993. PMID: 8478788

90. Tillinghast EK, Townley MA, **Wight TN**, Uhlenbruck G, Janssen E. The adhesive glycoprotein of the orb web of *Argiope aurantia* (Araneae, Araneidae). In: *Biomolecular Materials*, Viney C, Case ST, Waite JH, eds, Materials Research Society Symposium Proceedings, pp. 292:9-23, 1993.

91. Klebanoff SJ, Kinsella MG, **Wight TN**. Degradation of endothelial cell matrix heparan sulfate proteoglycan by elastase and the myeloperoxidase-H_2O_2 chloride system. *Am J Pathol* 143:907-917, 1993. PMID: 8395774

92. Iwata M, **Wight TN**, Carlson SS. A brain extracellular matrix proteoglycan forms aggregates with hyaluronan. *J Biol Chem* 268:15061-15069, 1993. PMID: 8325882

93. Qwarnström EE, Järveläinen HT, Kinsella MG, Ostberg CO, Sandell LJ, Page RC, **Wight TN**. Interleukin-1β regulation of fibroblast proteoglycan synthesis involves a decrease in versican steady-state mRNA levels. *Biochem J* 294:613-620, 1993. PMID: 8373377

PUBLICATIONS - continued

94. Yao LY, Moody C, Schönherr E, **Wight TN**, Sandell LJ. Identification of the proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, *in situ* hybridization and immunohistochemistry. *Matrix Biol* 14:213-225, 1994. PMID: 7921538

95. Nikkari ST, Järveläinen HT, **Wight TN**, Ferguson M, Clowes AW. Smooth muscle cell expression of extracellular matrix genes after arterial injury. *Am J Pathol* 144:1348-1356, 1994. PMID: 8203472

96. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, **Wight TN**. Regional differences in the distribution of proteoglycans biglycan and decorin in the extracellular matrix of atheroslcerotic and restenotic human coronary arteries. *Am J Pathol* 144:962-974, 1994. PMID: 8178945

97. Sekiguchi RT, Potter-Perigo S, Braun K, Miller J, Ngo C, Fukuchi K, **Wight TN**, Kimata K, Snow AD. Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation. *J Neurosci Res* 38:670-686, 1994. PMID: 7807583

98. Savani RC, Wang C, Yang B, Zhang S, Kinsella MG, **Wight TN**, Stern R, Nance DM, Turley EA. Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. *J Clin Invest* 95:1158-1168, 1995. PMID: 7533785

99. Snow AD, Kinsella MG, Parks E, Sekiguchi RT, Miller JD, Kimata K, **Wight TN**. Differenatial binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. *Arch Biochem Biophys* 320:84-95, 1995. PMID: 7793988

100. Ostberg CO, Zhu P, **Wight TN**, Qwarnstrom E. Fibronectin attachment is permissive for IL-1 mediated gene regulation. *FEBS Lett* 367:93-97, 1995. PMID: 7541375

101. **Wight TN**. The extracellular matrix and atherosclerosis. *Curr Opin Lipidol* 6:326-334, 1995. PMID: 8520856

102. Lemire JM, Potter-Perigo S, Hall KL, **Wight TN**, Schwartz SM. Distinct rat aortic smooth muscle cells differ in versican/PG-M expression. *Arterioscler Thromb Vasc Biol* 16:821-829, 1996. PMID: 8640411

103. Riessen R, **Wight TN**, Pastore C, Henley C, Isner JM. Distribution of hyaluronan during extracellular remodeling in human restenotic arteries and balloon-injured rat carotid arteries. *Circulation* 93:1141-1147, 1996. PMID: 8653834

104. Carlson SS, Iwata M, **Wight TN**. A chondroitin sulfate/keratan sulfate proteoglycan, PG-1000 forms complexes which are concentrated in the reticular laminae of electric organ basement membranes. *Matrix Biol* 15:281-292, 1996. PMID: 8892227

105. Potter-Perigo S, **Wight TN**. Heparin causes the accumulation of heparan sulfate in cultures of arterial smooth muscle cells. *Arch Biochem Biophys* 336:19-26, 1996. PMID: 8951030

PUBLICATIONS - continued

106. Halpert I, Sires UI, Roby JD, Potter-Perigo S, **Wight TN**, Shapiro SD, Welgus HG, Wickline SA, Parks WC. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. *Proc Nat Acad Sci USA* 93:9748-9753, 1996. PMID: 8790402

107. **Wight TN**. The vascular extracellular matrix. In: *Atherosclerosis and Coronary Artery Disease*, Fuster V, Ross R, Topol E, eds, Lippincott-Raven Publishers, pp. 421-440, 1996.

108. **Wight TN**. Extracellular matrices: Tissue function-arterial wall. In: *Structure and Function of the Extracellular Matrix of Connective Tissues*, Comper W, ed, Gordon and Breach Science Publishers, pp. 175-202, 1996.

109. Kinsella MG, Tsoi CK, Järveläinen HT, **Wight TN**. Selective expression and processing of biglycan during migration of bovine aortic endothelial cells: The role of endogenous basic fibroblast growth factor. *J Biol Chem* 272:318-325, 1997. PMID: 8995264

110. Schönherr E, Kinsella MG, **Wight TN**. Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. *Arch Biochem Biophys* 339:353-361, 1997. PMID: 9056268

111. **Wight TN**, Lara S, Riessen R, Le Baron R, Isner J. Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries. *Am J Pathol* 151:963-973, 1997. PMID: 9327730

112. Gutierrez P, O'Brien KD, Ferguson M, Nikkari ST, Alpers CE, **Wight TN**. Differences in the distribution of versican, decorin, and biglycan in atherosclerotic human coronary arteries. *Cardiovasc Pathol* 6:271-278, 1997.

113. Miller JD, Cummings J, Maresh GA, Walker DG, Castillo GM, Ngo C, Kimata K, Kinsella MG, **Wight TN**, Snow AD. Localization of perlecan (or a perlecan-related marcromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus. *Glia* 21:228-243, 1997. PMID: 9336237

114. Castillo GM, Ngo C, Cummings J, **Wight T**, Snow AD. Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation and maintains Aβ fibril stability. *J Neurochem* 69:2452-2465, 1997. PMID: 9375678

115. Roberts CR, **Wight TN**, Hascall VC. Proteoglycans. In: *The Lung: Scientific Foundations*, 2nd edition, Crystal R, West JB, eds, Lippincott Raven Publishers, pp. 757-767, 1997.

116. Jabbour AJ, Altman LC, Baker C, **Wight TN**, Luchtel D. Ozone alters the distribution of β_1 integrins in cultured primate bronchial epithelial cells. *Am J Respir Cell Mol Biol* 19:357-365, 1998. PMID: 9730863

117. Potter-Perigo S, Kaplan ED, Luchtel DL, Baker C, Altman LC, **Wight TN**. Ozone alters the expression of tenascin-C in cultured primate nasal epithelial cells. *Am J Respir Cell Mol Biol* 18:471-478, 1998. PMID: 9533934

PUBLICATIONS - continued

118. Evanko SP, Raines EW, Ross R, Gold LI, **Wight TN**. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-β. *Am J Pathol* 152:533-546, 1998. PMID: 9466580

119. Chang MY, Olin KL, Tsoi C, **Wight TN**, Chait A. Human monocyte-derived macrophages secrete two forms of proteoglycan-macrophage colony-stimulating factor that differ in their ability to bind low density lipoproteins. *J Biol Chem* 273:15985-15992, 1998. PMID: 9632647

120. Koyama N, Kinsella MG, **Wight TN**, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. *Circ Res* 83:305-313, 1998. PMID: 9710123

121. Borén J, Olin K, Lee I, Chait A, **Wight TN**, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL: a single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. *J Clin Invest* 101:2658-2664, 1998. PMID: 9637699

122. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, **Wight TN**, Chait A. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. *Circulation* 98:519-527, 1998. PMID: 9714108

123. Nikol S, Huehns TY, Weir L, **Wight TN**, Höfling B. Restenosis in human vein bypass grafts. *Atherosclerosis* 139:31-39, 1998. PMID: 9699889

124. Chait A, Chang Y, Olin K, O'Brien K, **Wight TN**. Interaction of oxidized LDL with arterial proteoglycans. In: *Atherosclerosis XI*, Jacotot B, Mathe D, Fukhart JC, eds, Elsevier, pp. 79-82, 1998.

125. Evanko SP, Angello JC, **Wight TN**. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 19:1004-1013, 1999. PMID: 10195929

126. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, **Wight TN**. Versican/PG-M isoforms in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 19:1630-1639, 1999. PMID: 10397680

127. Castillo GM, Lukito W, **Wight TN**, Snow AD. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. *J Neurochem* 72:1681-1687, 1999. PMID: 10098877

128. Evanko SP, **Wight TN**. Intracellular localization of hyaluronan in proliferating cells. *J Histochem Cytochem* 47:1331-1341, 1999. PMID: 10490462

129. Andrikopoulos S, Verchere CB, Teague JC, Howell WM, Fujimoto WY, **Wight TN**, Kahn SE. Two novel immortal pancreatic β-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. *Diabetes* 48:1962-1970, 1999. PMID: 10512360

PUBLICATIONS - continued

130. Olin KL, Potter-Perigo S, Barrett PH, **Wight TN**, Chait A. Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. *J Biol Chem* 274:34629-34636, 1999. PMID: 10574927

131. **Wight TN**. Hyaluronan in atherosclerosis and restenosis. Website Article: http://www.glycoforum.gr.jp/science/hyaluronan/HA09/HA09E.html, 1999.

132. **Wight TN**. Biosynthesis of proteoglycans. In: *Comprehensive Natural Product Chemistry*, Vol III, Barton D, Nakanishi K, eds, Elsevier, pp. 161-178, 1999.

133. Chang MY, Potter-Perigo S, Tsoi C, Chait A, **Wight TN**. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. *J Biol Chem* 275:4766-4773, 2000. PMID: 10671509

134. Fischer JW, Kinsella MG, Clowes MM, Lara S, Clowes AW, **Wight TN**. Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats. *Circ Res* 86:676-683, 2000. PMID: 10747004

135. Kaji T, Yamada A, Miyajima S, Yamamoto C, Fujiwara Y, **Wight TN**, Kinsella MG. Cell density-dependent regulation of proteoglycan synthesis by transforming growth factor-$ß_1$ in cultured vascular endothelial cells. *J Biol Chem* 275:1463-1470, 2000. PMID: 10625699

136. Kinsella MG, Fischer JW, Mason DP, **Wight TN**. Retrovirally mediated expression of decorin by macrovascular endothelial cells: effects on cellular migration and fibronectin fibrillogenesis *in vitro*. *J Biol Chem* 275:13924-13932, 2000. PMID: 10788518

137. Sindelar BJ, Evanko SP, Alonzo T, Herring SW, **Wight T**. Effects of intraoral splint wear on proteoglycans in the temporomandibular joint disc. *Arch Biochem Biophys* 379:64-70, 2000. PMID: 10864442

138. Kaneko E, Skinner MP, Raines EW, Yuan C, Rosenfeld ME, **Wight TN**, Ross, R. Detection of dissection and remodeling of atherosclerotic lesions in rabbits after balloon angioplasty by magnetic–resonance imaging. *Coron Artery Dis* 11:599-606, 2000. PMID: 11107507

139. **Wight TN**. Proteoglycans and hyaluronan in vascular disease. In: *Oligosaccharides in Chemistry and Biology*, Ernst B, Hart GW, Sinay P, eds, Wiley-VCH, pp. 744-755, 2000.

140. Chait A, **Wight TN**. Interaction of native and modified low-density lipoproteins with extracellular matrix. *Curr Opin Lipidol* 11:457-463, 2000. PMID: 11048888

141. Olin KL, Potter-Perigo S, Barrett PH, **Wight TN**, Chait, A. Biglycan, a vascular proteoglycan, binds differently to HDL_2 and HDL_3: role of apoE. *Arterioscler Thromb Vasc Biol* 21:129-135, 2001. PMID: 11145944

142. Chang MY, Potter-Perigo S, **Wight TN**, Chait A. Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices. *J Lipid Res* 42:824-833, 2001. PMID: 11352990

PUBLICATIONS - continued

143. Lee RT, Yamamoto C, Feng Y, Potter-Perigo S, Briggs WH, Landschulz KT, Turi TG, Thompson JF, Libby P, **Wight TN**. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. *J Biol Chem* 276:13847-13851, 2001. PMID: 11278699

144. Fischer JW, Kinsella MG, Levkau B, Clowes AW, **Wight TN**. Retroviral overexpression of decorin differentially affects the response of arterial smooth muscle cells to growth factors. *Arterioscler Thromb Vasc Biol* 21:777-784, 2001. PMID: 11348874

145. Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmerman DR, Lemire JM, Fischer JW, **Wight TN**, Clowes AW. Versican VI proteolysis in human aorta *in vivo* occurs at the Glu^{441}-Ala^{442} bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. *J Biol Chem* 276:13372-13378, 2001. PMID: 11278559

146. Lundmark K, Tran PK, Kinsella MG, Clowes AW, **Wight TN**, Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. *J Cell Physiol* 188:67-74, 2001. PMID: 11382923

147. Evanko SP, Johnson PY, Braun KR, Underhill CB, Dudhia J, **Wight TN**. Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. *Arch Biochem Biophys* 394:29-38, 2001. PMID: 11566024

148. Fischer JW, Kinsella MG, Hasenstab D, Clowes AW, **Wight TN**. Cell-mediated transfer of proteoglycan genes. *Methods Mol Biol* 171:261-269, 2001. PMID: 11450236

149. Lara SL, Evanko SP, **Wight TN**. Morphological evaluation of proteoglycans in cells and tissues. *Methods Mol Biol* 171:271-290, 2001. PMID: 11450238

150. Evanko S, **Wight TN**. Intracellular hyaluronan. Website article: http://www.glycoforum.gr.jp/science/hyaluronan/HA20/HA20E.html, 2001.

151. Lemire JM, Merrilees MJ, Braun KR, **Wight TN**. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion migration, and proliferation in vitro. *J Cell Physiol* 190:38-45, 2002. PMID: 11807809

152. Little PJ, Tannock L, Olin KL, Chait A, **Wight TN**. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-β1 exhibit increased binding to LDLs. *Arterioscler Thromb Vasc Biol* 22:55-60, 2002. PMID: 11788461

153. Tannock LR, Olin KL, Barrett PH, **Wight TN**, Chait A. Triglyceride-rich lipoproteins from subjects with type 2 diabetes do not demonstrate increased binding to biglycan, a vascular proteoglycan. *J Clin Endocrinol Metab* 87:35-40, 2002. PMID: 11788619

154. Tannock LR, Little PJ, **Wight TN**, Chait A. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. *J Lipid Res* 43:149-157, 2002. PMID: 11792734

PUBLICATIONS - continued

155. Merrilees MJ, Lemire JM, Fischer JW, Kinsella MG, Braun KR, Clowes AW, **Wight TN**. Retrovirally mediated overexpression of versican V3 by arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointima after vascular injury. *Circ Res* 90:481-487, 2002. PMID: 11884379

156. Kenagy RD, Fischer JW, Davies MG, Berceli SA, Hawkins SM, **Wight TN**, Clowes AW. Increased plasmin and serine protease activity during flow-induced intimal atrophy in baboon PTFE grafts. *Arterioscler Thromb Vasc Biol* 22:400-404, 2002. PMID: 11884281

157. Olin-Lewis K, Benton JL, Rutledge JC, Baskin DG, **Wight TN**, Chait A. Apolipoprotein E mediates the retention of high-density lipoproteins by mouse carotid arteries and cultured arterial smooth muscle cell extracellular matrices. *Circ Res* 90:1333-1339, 2002. PMID: 12089072

158. Yan Q, Clark JI, **Wight TN**, Sage EH. Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. *J Cell Sci* 115:2747-2756, 2002. PMID: 12077365

159. Finn AV, Gold HK, Tang A, Weber DK, **Wight TN**, Clermont A, Virmani R, Kolodgie FD. A novel rat model of carotid artery stenting for the understanding of restenosis in metabolic diseases. *J Vasc Res*, 39:414-425, 2002. PMID: 12297704

160. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, **Wight TN**. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. *J Am Coll Cardiol* 40:2072-2081, 2002. PMID: 12505216

161. Olin-Lewis K, Krauss RM, La Belle M, Blanche PJ, Barrett PH, **Wight TN**, Chait A. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan, biglycan. *J Lipid Res* 43:1969-1977, 2002. PMID: 12401896

162. Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, **Wight TN**, Virmani R. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. *Arterioscler Thromb Vasc Biol* 22:1642-1648, 2002. PMID: 12377743

163. Virmani R, Kolodgie FD, Burke AP, Farb A, **Wight TN**. Structural and cellular components of the vulnerable plaque: extracellular matrix. In: *Assessing and Modifying the Vulnerable Atherosclerotic Plaque*, Fuster V, ed, Futura Publishing Co., Inc., pp. 241-250, 2002.

164. Toole BP, **Wight TN**, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. *J Biol Chem* 277:4593-4596, 2002. PMID: 11717318

165. Järveläinen H, **Wight TN**. Vascular proteoglycans. In: *Proteoglycans in Lung Disease*, Garg HG, Roughley, PJ, Hales CA, eds, Marcel Dekker, p. 291-321, 2002.

166. **Wight TN**. Versican: a versatile extracellular matrix proteoglycan in cell biology. *Curr Opin Cell Biol* 14:617-623, 2002. PMID: 12231358

167. Evanko SP, **Wight TN**. The presence and processing of intracellular hyaluronan in proliferating cells. In: *Hyaluronan, Vol. 1: Chemical, Biochemical and Biological Aspects*, eds. Kennedy JF, Phillips GO, Williams PA, Hascall VC, Woodhead Publishing, pp. 451-456, 2002.

PUBLICATIONS - continued

168. **Wight TN,** Evanko SP. Hyaluronan is a critical component in atherosclerosis and restenosis and in determining arterial smooth muscle cell phenotype. In: *Hyaluronan, Vol. 2: Biomedical, Medical and Clinical Aspects*, Kennedy JF, Phillips GO, Williams PA, Hascall VC, eds, Woodhead Publishing, pp. 173-176, 2002.

169. Frevert CW, Kinsella MG, Vathanaprida C, Goodman RB, Baskin DG, Proudfoot A, Wells TN, **Wight TN**, Martin TR. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. *Am J Respir Cell Mol Biol* 28:464-472, 2003. PMID: 12654635

170. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, **Wight TN**, Sage EH. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. *J Invest Dermatol* 120:949-955, 2003. PMID: 12787119

171. Puolakkainen P, Bradshaw AD, Kyriakides TR, Reed M, Brekken R, **Wight T**, Bornstein P, Ratner B, Sage EH. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. *Am J Pathol* 162:627-635, 2003. PMID: 12547720

172. Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S, **Wight TN**, Leduc R, Apte SS. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to *Caenorhabditis elegans* GON-1. *J Biol Chem* 278:9503-9513, 2003. PMID: 12514189

173. Potter-Perigo S, Hull RL, Tsoi C, Braun KR, Andrikopoulos S, Teague J, Verchere CB, Kahn SE, **Wight TN**. Proteoglycans synthesized and secreted by pancreatic islet β-cells bind amylin. *Arch Biochem Biophys* 413:182-190, 2003. PMID: 12729615

174. O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, Marcovina S, **Wight TN**, Chait A, Albers JJ. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. *Circulation* 108:270-274, 2003. PMID: 12835223

175. Kinsella MG, Tran PK Weiser-Evans MC, Reidy M, Majack RA, **Wight TN**. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. *Arterioscler Thromb Vasc Biol* 23:608-614, 2003. PMID: 12615671

176. Chang MY, Tsoi C, **Wight TN**, Chait A. Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor. *Arterioscler Thromb Vasc Biol* 23:809-815, 2003. PMID: 12663372

177. Wrenshall LE, Platt JL, Stevens ET, **Wight TN**, Miller JD. Propagation and control of T cell responses by heparan sulfate-bound IL-2. *J Immunol* 170:5470-5474, 2003. PMID: 12759423

178. Meyers CD, Tannock LR, **Wight TN**, Chait A. Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. *J Lipid Res* 44:2152-2160, 2003. PMID: 12923222

PUBLICATIONS - continued

179. Andrikopoulos S, Hull RL, Verchere CB, Wang F, Wilbur SM, **Wight TN**, Marzban L, Kahn SE. Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide. *Am J Physiol Endocrinol Metab* 286:E418-424, 2004. PMID: 14613923

180. Järveläinen H, Vernon RB, Gooden MD, Francki A, Lara S, Johnson PY, Kinsella MG, Sage EH, **Wight TN**. Overexpression of decorin by rat arterial smooth muscle cells enhances contraction of type 1 collagen in vitro. *Arterioscler Thromb Vasc Biol* 24:67-72, 2004. PMID: 14615389

181. Hinek A, Braun KR, Liu K, Wang Y, **Wight TN**. Retrovirally mediated overexpression of versican V3 reverses impaired elastrogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. *Am J Pathol* 164:119-132, 2004. PMID: 14695326

182. Potter-Perigo S, Baker C, Tsoi C, Braun KR, Isenhath S, Altman GM, Altman LC, **Wight TN**. Regulation of proteoglycan synthesis by leukotriene d4 and epidermal growth factor in bronchial smooth muscle cells. *Am J Respir Cell Mol Biol* 30:101-108, 2004. PMID: 12855404

183. Burke AP, Järveläinen H, Kolodgie FD, Goel A, **Wight TN**, Virmani R. Superficial pseudoaneurysms: clinicopathologic aspects and involvement of extracellular matrix proteoglycans. *Mod Pathol* 17:482-488, 2004. PMID: 14976536

184. Tannock LR, Little PJ, Tsoi C, Barrett PH, **Wight TN**, Chait A. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. *Diabetologca* 47:837-843, 2004. PMID: 15071727

185. Wilkinson TS, Potter-Perigo S, Tsoi C, Altman LC, **Wight TN**. Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts. *Am J Respir Cell Mol Biol* 31:92-99, 2004. PMID: 14764429

186. Grande-Allen KJ, Calabro A, Gupta V, **Wight TN**, Hascall VC, Vesely I. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: associations with regions of tensile and compressive loading. *Glycobiology* 14:621-633, 2004. PMID: 15044391

187. Kinsella MG, Bressler S, **Wight TN**. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. *Crit Rev Eukaryot Gene Expr* 14:203-234, 2004. PMID: 15248816

188. **Wight TN**. The vascular extracellular matrix. In: *Atherothrombosis and Coronary Artery Disease*, Fuster V, Topel EJ, Nabel EG, eds, Lippincott Williams & Wilkins, pp. 421-438, 2005.

189. Hascall VC, Majors AK, de la Motte CA, Evanko SP, Wang A, Drazba JA, Strong SA, **Wight TN**. Intracellular hyaluronan: a new frontier for inflammation? *Biochem Biophys Acta* 1673:3-12, 2004. (*This paper was one of the top 10 papers downloaded from this journal in 2005.) PMID: 15238245

PUBLICATIONS - continued

190. **Wight TN**, Evanko S, Kinsella MG, Wilkinson T, Gouëffic Y, Huang R, Merrilees M. The pro-inflammatory nature of the extracellular matrix. In: *Atherosclerosis XIII*, Matsuzawa Y, Kita T, Nagai R, Teramoto T, eds, Elsevier, pp. 404-406, 2004.

191. Chait A, Lewis K, Tannock L, Retzlaff G, Kahn S, Knopp R, **Wight TN**. Nutrition and inflammation: role of dietary cholesterol. In: *Atherosclerosis XIII*, Matsuzawa Y, Kita T, Nagai R, Teramoto T, eds, Elsevier, pp. 313-316, 2004.

192. Lewis KE, Kirk EA, McDonald TO, Wang S, **Wight TN**, O'Brien KD, Chait A. Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice. *Circulation* 110:540-545, 2004. PMID: 15277327

193. **Wight TN**, Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. *Circ Res* 94:1158-1167, 2004. PMID: 15142969

194. Kinsella MG, Irvin C, Reidy MA, **Wight TN**. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. *Atherosclerosis* 175:51-57, 2004. PMID: 15186946

195. **Wight TN**, Evanko S, Kolodgie F, Farb A, Virmani R. Hyaluronan in atherosclerosis and restenosis. In: *Chemistry and Biology of Hyaluronan*, Garg HG, Hales CA, eds, Elsevier, pp. 307-321, 2004.

196. Nigro J, Ballinger ML, Dilley RL, Jennings GL, **Wight TN**, Little PJ. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding. *Diabetologia* 47:2105-2113, 2004. PMID: 15592811

197. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, **Wight TN**, Virmani R. Extracellular matrix changes in stented human coronary arteries. *Circulation* 110:940-947, 2004. PMID: 15302784

198. Kolodgie FD, Burke AP, **Wight TN**, Virmani R. The accumulation of specific types of proteoglycans in eroded plaques: a role in coronary thrombosis in the absence of rupture. *Curr Opin Lipidol* 15:575-582, 2004. PMID: 15361794

199. O'Brien KD, Lewis K, Fischer JW, Johnson P, Hwang JY, Knopp EA, Kinsella MG, Barrett PH, Chait A, **Wight TN**. Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. *Atherosclerosis* 177:29-35, 2004. PMID: 15488862

200. Fischer JW, Steitz SA, Johnson PY, Burke A, Kolodgie F, Virmani R, Giachelli C, **Wight TN**. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions of human atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 24:2391-2396, 2004. PMID: 15472131

201. Evanko SP, Parks WT, **Wight TN**. Intracellular hyaluronan in arterial smooth muscle cells: association with microtubules, RHAMM, and the mitotic spindle. *J Histochem Cytochem* 52:1525-1535, 2004. PMID: 15557208

202. Kaji T, Sakurai S, Yamamoto C, Fujiwara Y, Yamagishi S, Yamamoto H, Kinsella MG, **Wight TN**. Characterization of chondroitin/dermatan sulfate proteoglycans synthesized by bovine retinal pericytes in culture. *Biol Pharm Bull* 27:1763-1768, 2004. PMID: 15516719

PUBLICATIONS - continued

203. Puolakkaínen PA, Bradshaw AD, Brekken RA, Reed MJ, Kyriakides T, Funk SE, Gooden MD, Vernon RB, **Wight TN**, Bornstein P, Sage EH. SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. *J Histochem Cytochem* 53:571-581, 2005. PMID: 15872050

204. Kenagy RD, Fischer JW, Lara S, Sandy JD, Clowes AW, **Wight TN**. Accumulation and loss of extracellular matrix during shear stress-mediated intimal growth and regression in baboon vascular grafts. *J Histochem Cytochem* 53:131-140, 2005. PMID: 15637346

205. Vernon RB, Gooden MD, Lara SL, **Wight TN**. Microgrooved fibrillar collagen membranes as scaffolds for cell support and alignment. *Biomaterials* 26:3131-3140, 2005. PMID: 15603808

206. Vernon RB, Gooden MD, Lara SL, **Wight TN**. Native fibrillar collagen membranes of micron-scale and submicron thicknesses for cell support and perfusion. *Biomaterials* 26:1109-1117, 2005. PMID: 15451630

207. Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, **Wight TN**, Bassols A. V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. *Int J Cancer* 114:879-886, 2005. PMID: 15645431

208. O'Brien KD, McDonald TO, Kunjathoor V, Eng K, Knopp EA, Lewis K, Lopez R, Kirk EA, Chait A, **Wight TN**, deBeer FC, Le Boeuf RC. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. *Arterioscler Thromb Vasc Biol* 25:785-790, 2005. PMID: 15692094

209. **Wight TN**. The ADAMTS proteases, extracellular matrix, and vascular disease: waking the sleeping giant(s)! *Arterioscler Thromb Vasc Biol* 25:12-14, 2005. PMID: 15626768

210. Klüppel M, **Wight TN**, Chan C, Hinek A, Wrana JL. Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. *Development* 132:3989-4003, 2005. PMID: 16079159

211. Wilkinson TS, Bressler SL, Evanko SP, Braun KR, **Wight TN**. Overexpression of hyaluronan synthases alters vascular smooth muscle cell phenotype and promotes monocyte adhesion. *J Cell Physiol* 206:378-385, 2006. PMID: 16110480

212. L'Heureux N, Dusserre N, Konig G, Victor B, Keire P, **Wight TN**, Chronos NA, Kyles AE, Gregory CR, Hoyt G, Robbins RC, McAllister TN. Human tissue-engineered blood vessels for adult arterial revascularization. *Nat Med* 12:361-365, 2006. PMID: 16491087

213. Kinsella MG, **Wight TN**. Perlecan: an extracellular matrix heparan sulfate proteoglycan that regulates key events in vascular development. In: *Chemistry and Biology of Heparin and Heparan Sulfate*, Garg HG, Linhardt RJ, Hales CA, eds, Elsevier, pp. 611-640, 2005.

214. Otsuka G, Agah R, Frutkin AD, **Wight TN**, Dichek DA. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1–dependent pathways. *Arterioscler Thromb Vasc Biol* 26:737-743, 2006. PMID: 16373605

PUBLICATIONS - continued

215. Chang MY, Han CY, **Wight TN**, Chait, A. Antioxidants inhibit the ability of lysophosphatidylcholine to regulate proteoglycan synthesis. *Arterioscler Thromb Vasc Biol* 26:494-500, 2006. PMID: 16357313

216. Huang R, Merrilees MJ, Braun K, Beaumont B, Lemire J, Clowes AW, Hinek A, **Wight TN**. Inhibition of versican synthesis by antisense alters smooth muscle cell phenotype and induces elastic fiber formation *in vitro* and in neointima after vascular injury. *Circ Res* 98:370-377, 2006. PMID: 16385080

217. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, Ganesh S, Gordon LB, Virmani R, **Wight TN**, Nabel EG, Collins FS. Progressive vascular smooth muscle defects in a mouse model of Hutchinson-Gilford progeria syndrome. *Proc Nat Acad Sci USA* 103:3250-3255, 2006. PMID: 16492728

218. Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, Iozzo RV, Sage EH, **Wight TN**. A role for decorin in cutaneous wound healing and angiogenesis. *Wound Repair Regen* 14:443-452, 2006. PMID: 16939572

219. Kenagy RD, Plaas AH, **Wight TN**. Versican degradation and vascular disease. *Trends in Cardiovasc Med* 16:209-215, 2006. PMID: 16839865

220. Frevert C, **Wight TN**. Matrix proteoglycans. In *Encyclopedia of Respiratory Medicine,* Laurent GJ, Shapiro SJ, eds, Elsevier, pp 184-188, 2006.

221. Miguel-Serra L, Serra M, Hernandez D, Domenzain C, Docampo MJ, Rabanal RM, de Torres I, **Wight TN**, Fabra A, Bassols A. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. *Lab Invest* 86:889-901, 2006. PMID: 16847433

222. Kaji T, Yamamoto C, Oh-i M, Fujiwara Y, Yamazaki Y, Morita T, Plaas AH, **Wight TN**. The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells. *Biochim Biophys Acta* 1760:1465-1474, 2006. PMID: 16914267

223. Sullivan MM, Barker TH, Funk SE, Karchin A, Seo NS, Höök M, Sanders J, Starcher B, **Wight TN**, Puolakkainen P, Sage EH. Matricellular hevin regulates decorin production and collagen assembly. *J Biol Chem* 281:27621-27632, 2006. PMID: 16844696

224. Kuznetsova SA, Issa P, Perruccio EM, Zeng B, Sipes JM, Ward Y, Seyfried NT, Fielder HL, Day AJ, **Wight TN**, Roberts DD. Versican-thrombospondin-1 binding in vitro and colocalization in microfibrils induced by inflammation on vascular smooth muscle cells. *J Cell Sci* 119:4499-4509, 2006. PMID: 17046999

225. Tannock LR, Kirk EA, King VL, LeBoeuf R, **Wight TN**, Chait A. Glucosamine supplementation accelerates early but not late atherosclerosis in LDL receptor-deficient mice. *J Nutr* 136:2856-2861, 2006. PMID: 17056813

226. Kramer G, Laurie P, Neumann T, Rolle MW, **Wight TN**. Genetically Engineered for Increased Elastin Production Tissue Engineered Microvessels Composed of Smooth Muscle Cells. *J Undergrad Res Bioengineering (UW)* 6: 76-80, 2006.

PUBLICATIONS - continued

227. Johnson PY, Potter-Perigo S, Gooden MD, Vernon RB, **Wight TN**. Decorin synthesized by arterial smooth muscle cells is selectively retained in fibrin gels and modulates fibrin contraction. *J Cell Bochem*, 101:281-294, 2007. PMID: 17226774

228. Lemire JM, Chan CK, Bressler S, Miller J, LeBaron RG, **Wight TN**. Interleukin-1β selectively decreases the synthesis of versican by arterial smooth muscle cells. *J Cell Biochem*, 101:753-766, 2007. PMID: 17226775

229. Gouëffic Y, Potter-Perigo S, Chan CK, Johnson Y, Braun K, Evanko S, **Wight TN**. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. *Atherosclerosis*, 195:23-30, 2007. PMID: 17174314

230. Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, **Wight TN**, Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. *Atherosclerosis*, 195:100-109, 2007. PMID: 17214992

231. Kolodgie FD, Burke AP, Farb A, Fowler DR, Kutys R, **Wight TN**, Virmani R. Plaque erosion. In *The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management,* Virmani R, Narula J, Leon MB & Willerson JT, eds, Blackwell Publishing, pp. 60 - 76, 2007.

232. Nakashima Y, Fujii H, Sumiyoshi S, **Wight TN**, Sueishi K. Early human atherosclerosis: Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. *Arterioscler Thromb Vasc Biol*, 27:1159-65, 2007. PMID: 17303781

233. Bollyky PL, Lord JD, Masewicz SA, Evanko SP, Buckner JH, **Wight TN**, Nepom GT. High molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T-cells. *J Immunol*, 179:744-747, 2007. PMID: 17617562

234. Han CY, Subramanian S, Chan CK, Omer M, Chiba T, **Wight TN**, Chait A. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. *Diabetes*, 56:2260-2273, 2007. PMID: 17563062

235. McDonald TO, Gerrity RG, Jen C, Chen HJ, Wark K, **Wight TN**, Chait A, O'Brien KD. Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis. *J Histochem Cytochem*, 55:1149-57, 2007. PMID: 17652266

236. Evanko SP, Tammi, MI, Tammi, RH, **Wight, TN.** Hyaluronan-dependent pericellular matrix. *Adv Drug Deliv Rev*, 59:1351-65, 2007. PMID: 17804111

237. Hull R, Zraika S, Udayasankar J, Kisilevsky R, Szarek WA, **Wight TN**, Kahn SE. Inhibition of glycosaminoglycans synthesis and protein glycosylation with WAS-405 and Azaserine result in reduced islet amyloid formation *in vitro*. *Am J Physiol Cell Physiol,* 293:C1586-93, 2007. PMID: 17804609

238. Allison DD, Vasco N, Braun KR, **Wight TN**, Jane Grande-Allen K. The effect of endogenous overexpression of hyaluronan synthases on material, morphological, and biochemical properties of uncrosslinked collagen biomaterials. *Biomaterials,* 28:5509-17, 2007. PMID: 17869336

PUBLICATIONS - continued

239. Miller JD, Stevens ET, Smith DR, **Wight TN**, Wrenshall LE. Perlecan: a major IL-2-binding proteoglycan in murine spleen. *Immunol Cell Biol,* 86(2):192-9, 2008. PMID: 18040286

240. Lowry MH, McAllister BP, Jean JC, Brown LS, Hughey RP, Cruikshank WW, Amar S, Lucey EC, Braun K, Johnson P, **Wight TN**, Joyce-Brady M. Lung lining fluid glutathione attenuates IL-13 induced asthma. *Am J Respir Cell Mol Biol*, 38:509-16. 2008. PMID: 18063838

241. Nakashima Y, **Wight TN**, Sueishi K. Early atherosclerosis in humans: Role of diffuse intimal thickening and extracellular matrix proteoglycans. *Cardiovasc Res*, In press, 2008. PMID: 18430750

242. Allison DD, **Wight TN**, Ripp NJ, Braun KR, Grande-Allen KJ. Endogenous overexpression of hyaluronan synthases within dynamically cultured collagen gels: Implications for vascular and valvular disease. *Biomaterials.* 20:2969-76, 2008. PMID: 18433861

243. Merrilees MJ, Ching PS, Beaumont B, Hinek A, **Wight TN**, Black PN. Changes in elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonay disease. *Respir Res.* 9:41, 2008. PMID: 18485243

244. **Wight TN**. Arterial remodeling in vascular disease: a key role for hyaluronan and versican. *Front Biosci*. 13:4933-4937, 2008. PMID: 18508558

245. Tran-Lundmark K, Tran PK, Paulsson-Berne G, Fridén V, Soininen R, Tryggvason K, **Wight TN**, Kinsella MG, Borén J, Hedin U. Heparan sulfate in perlecan promotes mouse atherosclerosis. Roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. *Circ Res.* In Press, 2008. PMID: 18535261

BOOKS

1. **Wight TN**, Mecham RP, eds. *The Biology of the Extracellular Matrix: Proteoglycans*, Academic Press, NY, 1987.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS

1. "Connective Tissue in Atherogenesis." FASEB Meeting, Atlanta, Georgia, 1981.
2. "Morphology of Proteoglycans." First Latin-American Congress on Cell Biology, Maracaibo, Venezuela, 1983.
3. "Proteoglycans: Structure and Function." American Lung Association Meeting, Anaheim, California, 1985.
4. Session Chair, Gordon Research Conference on Atherosclerosis, June, 1985.
5. "Proteoglycans in Vascular Disease." Medical Colleges of Beijing and Xian, China, October 1985.
6. "Vascular Proteoglycans." Gordon Research Conference, August 1992.
7. "Importance of Proteoglycans in Vascular Tissue." Tissue Engineering, Keystone Symposium, Keystone, CO, April 1991.
8. "Proteoglycans and Atherosclerosis." Workshop on Diabetes and Atherosclerosis, NIH, Bethesda, Maryland, September 1992.
9. "Extracellular Matrix in Aging-Proteoglycans." Sponsored by NIA, Santa Barbara, California, July 1992.
10. "Vascular Proteoglycans." Symposium to Honor Gardiner McMillan, NIH, Bethesda, Maryland, October 1992.
11. "Proteoglycans in Vascular Tissue." British Connective Tissue Society Meeting, London, England, 1991.
12. "Vascular Biology of Proteoglycans." University of Wales, Cardiff, Wales, 1991.
13. "Proteoglycans in Vascular Biology." Glycobiology - New Perspectives on Human Disease, NIH, Bethesda, Maryland, September 1993.
14. "Proteoglycans in Atherosclerosis." 62nd Annual Meeting of Royal College of Physicians and Surgeons of Canada, Vancouver, BC, Canada, September 1993.
15. "Regulation of Proteoglycan Synthesis." American Heart Association Annual Meeting, Atlanta, Georgia, November 1993.
16. "Proteoglycans in Vascular Biology." 22nd Annual Meeting of the Society for Complex Carboyhydrates, Puerto Rico, 1993.
17. "Regulation of Proteoglycan Synthesis by Vascular Cells." FASEB Annual Meeting, Anaheim, California, April 1994.
18. "The Biology of Vascular Proteoglycans." Third Brazilian Symposium of Extracellular Matrix, Angros dos Reis, Brazil, September 1994.
19. "Vascular Proteoglycans." International Symposium on Atherosclerosis, Montreal, Canada, October 1994.
20. Session Chair, "Extracellular Matrix in Vascular Biology." American Heart Association Meeting, Dallas, Texas, December 1994.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

21. "Regulation of Extracellular Matrix Metabolism in Atherosclerosis and Restenosis." Functional and Structural Aspects of the Vascular Wall, American Heart Association Conference, Snowbird, Utah, 1994.
22. "Overview of Proteoglycan Chemistry and Biology." Deuel Conference on Lipids, Monterey, California, 1995.
23. Session Chair, "Extracellular Matrix and Cell Adhesion." FASEB Meeting, Atlanta, Georgia, 1995.
24. "Proteoglycans in Atherosclerosis and Restenosis." Visiting Professor, Department of Bioengineering, Cleveland Clinic, Cleveland, Ohio, May 1996.
25. "Proteoglycans and Restenosis." Restenosis Summit VIII, Cleveland, Ohio, May 1996.
26. "Extracellular Matrix in Atherosclerosis." European Vascular Biology Meeting, Gothenberg, Sweden, June 1996.
27. Session Chair, "Vascular Matrix." IXth International Symposium on Atherosclerosis, Seattle, Washington, September 1996.
28. "Interactions of Lipoproteins with Extracellular Matrix." International Symposium on Nutrition and Atherosclerosis, Shirahama, Japan, December 1996.
29. "Regulation of Smooth Muscle Cell Proteoglycans." Deuel Conference on Lipids, Stevenson, Washington, April 1997.
30. "Extracellular Matrix and Cell Behavior." FASEB Meeting, New Orleans, Louisiana, May 1997.
31. Symposium Chair, "Matrix and Remodeling in Atherogenesis." XIXth Annual Meeting, International Society for Heart Research, Vancouver, BC, Canada, July 1997.
32. "Proteoglycans and Hyaluronan: Regulators of Vascular Cell Phenotype." Vascular Aspects of Ischemic Heart Disease, American Heart Association, Lake Tahoe, Nevada, February 1998.
33. "The Role of Matrix in Post-Angioplasty and Stent Restenosis." Fourth Local Drug Delivery Meeting and Cardiovascular Course, Geneva, Switzerland, February 1998.
34. "Proteoglycans and Hyaluronan: Key Components in Atherosclerosis and Restenosis." Biology of the Vessel Wall, Munster, Germany, September, 1998
35. Session Co-Chair, "Extracellular Matrix." American Heart Association 71st Meeting, Dallas, Texas, November 1998.
36. "Proteoglycans in Vascular Extracellular Matrix." Extracellular Matrix in Diabetes and Atherosclerosis, Seattle, WA, May 1999.
37. "Extracellular Matrix in Vascular Disease." Swedish National Network Cardiovascular Workshop, Gothenberg, Sweden, October, 1999.
38. "Proteoglycans in Restenosis." Sixth Local Drug Delivery Meeting, Geneva, Switzerland, February 2000.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

39. "Proteoglycans are Key Extracellular Matrix Molecules in Atherosclerosis and Restenosis." Visiting Professor, Cleveland Clinic, Department of Bioengineering, May 2000.

40. "The Importance of Proteoglycans in Atherosclerosis." Maine Medical Center Research Institute, South Portland, Maine, May 2000.

41. "The Role of Proteoglycans in Vascular Disease." American Diabetes Association Annual Meeting, San Antonio, Texas, June 2000.

42. "Proteoglycans: A Modulator of Vascular Pathogenesis." XVth International Congress on Fibrinolysis and Proteolysis, Hamamatsu, Japan, June 2000.

43. "Proteoglycans and Hyaluronan in Atherosclerosis and Restenosis." International Symposium of Atherosclerosis, Stockholm, Sweden, June 2000.

44. "Cell-Mediated Proteoglycan Gene Transfer Alters Vascular Cell Phenotype and the Development of Vascular Lesions." Gordon Research Conference on Proteoglycans, Andover, New Hampshire, July 2000.

45. "Hyaluronan in Atherosclerosis and Restenosis." Hyaluronan 2000, Wrexham, Wales, September 2000.

46. "Proteoglycans are Regulators of Vascular Cell Phenotype." International Congress of Vascular Biology, Geneva, Switzerland, September, 2000.

47. "Importance of Proteoglycans and Hyaluronan in Diabetes." Australian Vascular Biology Meeting, Marysville, Australia, October, 2000.

48. "Proteoglycan and Hyaluronan as Regulators of Vascular Cell Phenotype." Australian Vascular Biology Meeting, Marysville, Australia, October 2000.

49. "Proteoglycans and Hyaluronan are Molecules that Regulate Key Events in Atherosclerosis and Restenosis." Visiting Professor, University of Toronto, March 2001.

50. "Proteoglycans as Regulators of Elastic Fiber Formation." Gordon Research Conference on Elastin & Elastic Fibers, Meriden, New Hampshire, July 2001.

51. "Extracellular Matrix Abnormalities – Clues from the Cardiovascular System." Joint Workshop on Hutchinson-Gilford Progeria Syndrome, NIH, Bethesda, Maryland, November 2001.

52. "Lung Remodeling in Asthma." Northwest Asthma and Allergy Meeting, Glaxo SmithKline, Phoenix, Arizona, February 2002.

53. "Proteoglycans in Atherosclerosis and Restenosis." XIIth International Vascular Biology Meeting, Karuizawa, Japan, May 2002.

54. "Proteoglycans and Hyaluronan and the Vascular Complications of Diabetes." Diabetes Endocrinology Research Center Symposium, University of Washington, Seattle, Washington, May 2002.

55. "Use of Proteoglycan Genes for the Creation of Elastic Tissue Sheets and Small Caliber Prosthetic Vessels." Gordon Research Conference on Proteoglycans, Andover, New Hampshire, July 2002.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

56. "Cardiovascular Uses for Hyaluronan Oligosaccharides." Hyaluronan Oligosaccharide Workshop, Woods Hole, Massachusetts, July 2002.

57. "Role of Hyaluronan in Atherosclerosis and Restenosis." American Heart Association Workshop on Extracellular Matrix," Chicago, Illinois, November, 2002.

58. "Hyaluronan in the Cardiovascular System." Hyaluronan Conversations Workshop, St. Tropez, France, June 2003.

59. "Elastin-Proteoglycan Interactions." Gordon Research Conference on Elastin & Elastic Fibers, Meriden, New Hampshire, August, 2003.

60. "Proteoglycans in Cardiovascular Disease." Pathobiology of Proteoglycans, Parma, Italy, September, 2003.

61. "The Pro-Inflammatory Nature of the Extracellular Matrix." XIIIth International Symposium on Atherosclerosis, Kyoto, Japan, September, 2003.

62. "Hyaluronan in the Cardiovascular System." Hyaluronan 2003, Cleveland, Ohio, October, 2003.

63. "Use of Hyaluronan Oligosaccharides in Cardiovascular Disease." Hyaluronan Oligosaccharide Workshop, Cleveland, Ohio, October, 2003.

64. "The Importance of Extracellular Matrix Proteoglycans in Atherosclerosis and Restenosis." 44th Annual Meeting of the Japanese College of Angiology, Fukuoka, Japan, November, 2003.

65. "The Response to Retention Hypothesis of Atherosclerosis: Is there a Universal Theme?" 44th Annual Meeting of the Japanese College of Angiology, Fukuoka, Japan, November, 2003.

66. "The Use of Proteoglycan Genes to Engineer Vascular Tissue." 8th Annual Workshop at Hilton Head on Cardiovascular Tissue Engineering, Hilton Head, South Carolina, March, 2004

67. Chair, "Cell Matrix Interactions." The 18th International Vascular Biology Meeting, Toronto, Canada, June, 2004.

68. "Versican or Versicant: Key Regulators of Vascular Cell Phenotype." Gordon Conference on Proteoglycans, Andover, New Hampshire, July, 2004.

69. Co-Chair and Speaker, "Extracellular Matrix and Inflammation." 12th International Congress of Histochemistry and Cytochemistry, San Diego, California, July, 2004.

70. Co-Chair, "Versican – Master Regulation of Vascular Cell Phenotype and Extracellular Matrix Assembly," American Society for Matrix Biology, San Diego, California, November, 2004.

71. Panel Discussant, "Tissue Engineering: Where in the World, Will We Get the Cells?" Engineering Tissues, Hilton Head Workshop, Hilton Head, South Carolina, March 2005.

72. "Proteoglycans, Cells and Elastogenesis." Gordon Conference on Elastin & Elastic Fibers, Waterville Valley, New Hampshire, July 2005.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

73. "Extracellular Matrix." Workshop on Vulnerable Atherosclerotic Plaque, NIH, Bethesda, Maryland, September, 2005.

74. "Lung Extracellular Matrix: Alterations in Response to Enantiomers of Albuterol." Scientific Forum, Sepracor, Boston, Massachusetts, September 2005.

75. "Versican in Atherosclerosis and Restenosis." American Heart Association Meeting, Dallas, Texas, November 2005.

76. "Proteoglycans." 4th International Vulnerable Plaque Meeting, Capri, Italy, May 2006.

77. "Hyaluronan and Versican: Partners in Crime in Vascular Disease." Extracellular Glycomatrix in Health and Disease, Awaji Island, Japan, June 2006.

78. "The Pro-Inflammatory Nature of the Extracellular Matrix." Satellite Meeting – New Developments in Atherosclerosis Research in Pharmaceutical Sciences, Kameoka, Japan, June 2006.

79. Conference Vice-Chair, Gordon Research Conference on Proteoglycans, Andover, New Hampshire, July 2006.

80. Session Chair, "Proteoglycans in Injury and Inflammation." Gordon Research Conference on Proteoglycans." Andover, New Hampshire, July 2006.

81. Session Co-Moderator, "Natural History of Atherosclerosis." American Heart Association Meeting, Chicago, Illinois, November 2006.

82. Session Co-Moderator, "Extracellular Matrix in Vascular Remodeling." American Heart Association Meeting, Chicago, Illinois, November 2006.

83. "Lung Extracellular Matrix in Asthma: Alterations in Response to Enantiomers of Albuterol" , Sepracor Scientific Forum, Naples, FL, February 2007

84. Session Co-Chair at the Annual Hilton Head Workshop, Engineering Tissues: Replace, Repair, Regenerate, Hilton Head, SC, March, 2007.

85. "The use of proteoglycan genes to engineer extracellular matrix assembly." Vascular Matrix Biology and Bioengineering Workshop, Whistler, BC, March 2007.

86. Session Chair, "Vascular Matrix in Disease." Vascular Matrix Biology and Bioengineering Workshop, Whistler, BC, March 2007.

87. "Proteoglycans as Therapy," 5th International Vulnerable Plaque Meeting, Santorini, Greece, June 2007.

88. "Arterial Remodeling in Vascular Disease: A Key Role for Hyaluronan and Versican," Inaugural International Conference in Cerebrovascular Disease, Manchester, UK, July 2007.

89. Session Chair, "Adipose Tissue, Inflammation and Vascular Risk," American Heart Association Meeting, Orlando , FL, November 2007.

90. "Models for Generating Tissue-Engineered Blood Vessels," American Heart Association Meeting, Orlando, FL, November 2007.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

91. "Hyaluronan and Versican: Regulators of Key Inflammatory Events in Vascular Disease," Invited Faculty and Speaker at 4th Finnish Glycoscience Graduate Course and Meeting, Rautavaara, Finland, November 2007.

92. "Pancreatic Extracellular Matrix in Autoimmune Disease," Autoimmunity Prevention Center Meeting (NIH), Stanford University School of Medicine, Palo Alto, CA, March 2008.

93. Session Chair, "Laser Capture Microdissection for Molecular Analysis," Experimental Biology Annual Meeting, San Diego, CA, April 2008.

INVITED RESEARCH SEMINARS

1. Cornell University Medical School, New York, NY, November 1982
2. Boston University School of Medicine, Boston, MA, May 1982
3. NIDR, Bethesda, MD, September 1985
4. Rush Presbyterian - St. Luke's Medical Center, Chicago, IL, November 1985
5. Cornell University Medical School, New York, NY, November 1987
6. La Jolla Cancer Center, La Jolla, CA, October 1987
7. Jefferson Medical College, Philadelphia, PA, May 1989
8. Merck, Sharpe and Dohme, Rahway, NJ, May 1989
9. University of Alabama, Birmingham, AL, May 1989
10. Washington University, St. Louis, MO, June 1990
11. Telios Pharmaceuticals, La Jolla, CA, April 1993
12. University of Minnesota, Minneapolis, MN, March 1993
13. University of British Columbia,Vancouver, B.C., September 1994
14. Thomas Jefferson University, Philadelphia, PA, October 1994
15. Gladstone Foundation, San Francisco, CA, May 1995
16. Cleveland Clinic, Cleveland, OH, October 1996
17. University of Michigan, Ann Arbor, MI, September 1997
18. Parke-Davis, Ann Arbor, MI, September 1997
19. Gladstone Foundation, San Francisco, CA, January 1998
20. Institute of Atherosclerosis Research, Munster, Germany, September, 1998
21. Karolinska Institute, Stockholm, Sweden, October, 1999
22. Wallenberg Cardiovascular Laboratories, Gothenberg, Sweden, October, 1999
23. Research Servier, Suresnes, France, February 2000
24. University of Zurich, Zurich, Switzerland, February 2000
25. University of Washington, Department of Pathology, March 2000
26. Department of Biochemistry, University of Kanazawa, Japan, June, 2000
27. Armed Forces Institute of Pathology, Washington, DC, June 2000
28. Columbia University, Department of Medicine, New York, NY, December 2000
29. Cornell Medical College, Department of Pathology, New York, NY, December 2000
30. Abbott Laboratories, Chicago, IL, May 2001
31. Guidant Corporation, San Francisco, CA, June 2001
32. Boston Scientific, Minneapolis, MN, August 2001
33. Medical University of South Carolina, SC, October 2001
34. Georgia Tech School of Biomedical Engineering, Atlanta, GA, January 2002.

INVITED RESEARCH SEMINARS - Continued

35. Center for Extracellular Matrix Biology, Texas A and M University, April 2003
36. Tufts School of Medicine, Boston, Massachusetts, May 2003
37. Cleveland Clinic, Cleveland, Ohio, May 2003
38. Berlex, San Francisco, California, July 2003
39. University of Toronto, Department of Biochemistry, July 2003
40. EPIX Medical, Cambridge, Massachusetts, August 2003
41. University of Minnesota, Dept. of Pathology and Laboratory Medicine, December 2003
42. University of Washington, Department of Pulmonary and Critical Care, January, 2004
43. University of Washington, Department of Bioengineering, February 2004
44. University of Iowa, Department of Medicine, February, 2004
45. Benaroya Research Institute, Seattle, Washington, March 2004
46. Astra Zeneca, Gothenberg, Sweden, April 2004
47. University of Kentucky (Visiting Professor) October 2004
48. Northwestern University, Evanston, Illinois, April 2005
49. Harvard Medical School, Department of Pathology, Boston, Massachusetts, January 2006
50. University of Utrecht School of Veterinary Medicine, The Netherlands, March 2006
51. University of Dusseldorf, Department of Pharmacology, Germany, March 2006
52. Boston University, Department of Biochemistry, Massachusetts, March 2006
53. Boston Biomedical Institute, Watertown, Massachusetts, March 2006
54. Lilly Corporate Center, Indianapolis, Indiana, May 2006
55. University of Washington, Department of Regenerative Medicine, Seattle, May 2006
56. Hokuriku University, Kanazawa, Japan, June 2006.
57. Grand Rounds, Virginia Mason Medical Center, Seattle, Washington, June 2006
58. University of Washington, Biomaterials Short Course, Seattle, February, 2007
59. Cornell University, Weill Medical College, March, 2007
60. Division of Preventive Medicine and Nutrition, Columbia University, March, 2007
61. Strang Cancer Prevention Center, The Rockefeller University, March, 2007
62. Cleveland Clinic, Cleveland, Ohio, May, 2007
63. Welcome Trust Center for Cell-Matrix Research, Manchester, UK, July 2007
65. Department of Pathology, University of Washington, Seattle, July 2007
66. Excellence Cluster Cardio-Pulmonary System Seminar Series, Bad Nauheim, Germany, September 2007
67. Department of Bioengineering, Rice University, Houston, TX, October 2007
68. Department of Medicine, Turku University Central Hospital, Turku, Finland, December 2007
69. Johnson & Johnson, Princeton, NJ, January 2008
69. Genzyme Inc., Framingham, MA, April 2008

ABSTRACTS (Selected)

1. **Wight TN**, Cooke PH, Smith SM. An electron microscopic study of developing pigeon aorta cell *in vitro*. *J Cell Biol* 67:2, 1975.
2. Curwen KD, **Wight TN**. Similarities in glycosaminoglycan content of pigeon arteries and arterial cell cultures. *J Cell Biol* 75(2), 1977.
3. Harris S, Gajdusek C, Schwartz S, **Wight T**. Role of endothelial cell products in vascular growth responses and neovascularization. *J Cell Biol* 83(2):118a, 1979.
4. Tveter-Gallagher E, **Wight TN**, Cheney D. Effects of the phycocolloid carrageenan on human fibroblasts *in vitro*. A preliminary study. *J Cell Biol* 83(2):118a, 1979.
5. **Wight TN**, Curwen KD, Homan W, Minick C. Effect of regenerated endothelium on glycosaminoglycan accumulation in the arterial wall. *Fed Proc* 38(3):1075, 1979.
6. **Wight TN**, Hascall VC, Ross R. Synthesis and secretion of proteoglycans by primater arterial smooth muscle cells during growth stimulation *in vitro*. *J Cell Biol* 87(2)119a, 1980.
7. Iozzo RV, **Wight TN**, Bolender RP. Integrated biochemical and sterological analysis of proteoglycans in the intercellular matrix of human colon carcinoma. *J Cell Biol* 87(2)123a, 1980.
8. Iozzo RV, Armstrong C, **Wight TN**. Biochemical and ultrastructural studies of proteoglycans in humancolon carcinoma. *Fed Proc* 39(4):1019, 1980.
9. Oohira A, **Wight TN**, McPherson J, Bornstein P. Biochemical and ultrastructural studies of proteo-heparan sulfates synthesized by PYS-2, a basement membrane producing cell line. *J Cell Biol* 9(12);162a, 1981.
10. Schmidt R, **Wight TN**, Habenicht A, Glomset J, Ross R. Maintenance of 3T3 cell shape requires mevalonic acid. *J Cell Biol* 91(2):297a, 1981.
11. **Wight TN**, Hascall VC, Ross R. The synthesis and secretion of proteoglycans by arterial smooth muscle cells cultured from nonhuman primates. *Fed Proc* 41(3):269, 1982.
12. Clowes AW, Clowes MM, Gown AM, **Wight TN**. Distribution of proteoheparan sulfate in rat aorta. *Fed Proc* 41(3):441, 1982.
13. Iozzo RV, Carns JL, Poole AR, Rosenberg L, **Wight TN**. Immunochemical localization of various proteoglycans in human colon and colon carcinoma. *Fed Proc* 41(3):616, 1982.
14. Oohira A, **Wight TN**, Bornstein P. Synthesis of proteoglycans by vascular endothelial cells. *Fed Proc* 41(3):864, 1982.
15. Marroquin R, Iozzo RV, Birdsell D, **Wight TN**. Analysis of proteoglycans by high PLC. *Fed Proc* 41(4):1438, 1982.
16. Kinsella MG, **Wight TN**. Modulation of sulfated proteoglycan metabolism by cultured aortic endothelial cells during migration. *J Cell Biol* 99(4):173a, 1984.
17. Lark MW, **Wight TN**. Effect of a collagenous extracellular matrix on proteoglycan metabolism by aortic smooth muscle cells. *J Cell Biol* 99(4):174a, 1984.

ABSTRACTS (Selected) - Continued

18. Garrigues HJ, Lark MW, Hellström KE, **Wight TN**. Chondroitin sulfate proteoglycan as a marker for melanoma. *J Cell Biol* 99(4):386a, 1984.

19. Lark MW, Hellström I, Hellström KE, **Wight TN**. Characterization of a monoclonal antibody directed against arterial wall chondroitin sulfate proteoglycan. *J Cell Biol* 101(5):337a, 1985.

20. Kinsella MF, **Wight TN**. Structure and metabolism of sulfated proteoglycan in wounded and confluent cultures of bovine aortic endothelial cells. *J Cell Biol* 101(5):338a, 1985.

21. Snow AD, Mar H, Nochlin D, **Wight TN**. Corpora amylacea in aging and Alzheimer's brain contains antigenic sites for chondroitin sulfate and heparan sulfate proteoglycans. Vth International Symposium on Amyloidosis, 1987.

22. Snow AD, Kisilevsky R, **Wight TN**. Immunolocalization of heparan sulfate proteoglycans to AA amyloid deposition sites in spleen during experimental amyloidosis. Vth International Symposium of Amyloidosis, 1987.

23. Juul SE, Hodson WA, **Wight TN**. Proteoglycan changes with development in the non-human primate (*Macaca nemestrina*) lung. *J Cell Biol* 109:233a, 1989.

24. Järveläinen H, Kinsella MG, Sandell LJ, **Wight TN**. The small dermatan sulfate proteoglycan II (PG-II) is expressed by bovine arterial smooth muscle cells but not by endothelial cells. *J Cell Biol* 109:233a, 1989.

25. Schönherr E, Sandell LJ, **Wight TN**. Differential effect of PDGF and TGF-β on proteoglycan and DNA synthesis by cultured arterial smooth muscle cells and chondrocytes. *J Cell Biol* 109:234a, 1989.

26. Kaplan ED, **Wight TN**. Differential expression of tenasin isoforms during human skin development. *ASCB Abstracts*, 1994.

27. Olin KL, Chait AC, **Wight TN**. Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to biglycan and versican. *Circulation* 96S:I-40, 1996.

28. Fischer JW, Davies MG, **Wight TN**, Clowes AW. Versican is the predominant proteoglycan in flow accelerated neointimal hyperplasia of endothelialized baboon vascular grafts. *Circulation* 98S: I-228, 1998.

29. Boren J, Olin KL, Arnold KS, Ludwig EH, **Wight TN**, Chait AC, Innerarity T. Engineering non-atherogenic low density lipoproteins – direct evidence for the response to retention hypothesis. *Circulation* 98S: I-314, 1998.

30. Olin KL, Kunjathor VV, DeBeer F, **Wight TN**, Chait A, LeBoeuf RC, O'Brien KD. Co-localization of serum amyloid A with apolipoprotein A-1 and perlecan in lesions of atherosclerosis-prone mice. *Circulation* 100S: I-400, 1999.

31. Olin KL, Benton JL, Rutledge JM, O'Brien KD, **Wight TN**, Chait A. ApoE facilitates the retention of HDL on extracellular matrix i*n vitro* and on murine carotid arteries *in situ*. *Circulation* 100S: I-539, 1999.

32. Olin KL, Krauss RM, La Belle M, Hokanson JE, **Wight TN**, Chait A. ApoCIII modulates lipoprotein binding to the vascular proteoglycan, biglycan. *Circulation* 100S: I-693, 1999.

ABSTRACTS (Selected) - Continued

33. Olin KL, O'Brien, KD, DeBeer F, Kindy MS, **Wight TN**, Chait A. Serum amyloid A mediates the binding of HDL to vascular proteoglycans. *Circulation* 100S: I-706, 1999
34. Davies MG, Fischer JW, Kenagy R, **Wight TN**, Clowes AW. Time course of flow induced neointimal atrophy in endothelialized baboon vascular grafts. *Circulation* 100S: I-708, 1999.
35. Evanko SP, **Wight TN**. Critical roles of hyaluronan and versican during proliferation of vascular smooth muscle cells. *Circulation* 100S: I708, 1999.
36. Fischer JW, Kinsella MG, Clowes MM, Clowes AW, **Wight TN**. Local expression of bovine decorin reduces neointima formation after arterial injury in rats. *Circulation* 100S: I-753, 1999.

PARTICIPATING MEMBER OF THE FOLLOWING TRAINING GRANTS

T32 HL07312:	Experimental Pathology of Cardiovascular Disease	
	1983 - present	(PI: S. Schwartz)
T32 GM07266:	Medical Science Training Program	
	1984 - present	(PI: L. Loeb)
T32 DE07063:	Dentist Scientist Training Program	
	1986 - 2002	(PI: R. Page)
T32 GM07270:	Molecular and Cell Biology	
	1987 - present	(PI: D. Kimelman)
T32 AG00057	Genetic Approaches to Aging Research	
	1983 - present	(PI: P. Rabinovitch)
T32 HL007828-11:	Cardiovascular Research Training Grant	
	1997 - present	(PI: D. Dichek)
T32 DK007247	Metabolism Training Grant	
	1998 - present	(PI: Michael Schwartz)

TRAINEES

Ph.D. Thesis Committee

Ms. Robin Heller-Harrison	Pathobiology/UW	1980 - 1985
Mr. Everett Nichols	Pathobiology/UW	1982 - 1986
Ms. Susanne Mumby	Biochemistry/UW	1982 - 1984
Mr. Jacques Garrigues	Pathology (Chairman)/UW	1983 - 1988
Mr. Russell Faust	Pathology/UW	1986 - 1988
Ms. Arlene Wechezak	Pathology (Chairman)/UW	1985 - 1989
Mr. Mark Robinson	Biostructure/UW	1982 - 1985
Mr. Rod Schmidt	Biochemistry/UW	1982 - 1985
Ms. Eileen Bryant	Pathology/UW	1979 - 1981
Mr. Howard Coleman	Pathology/UW	1987 - 1990
Mr. Paul Andreassen	Pathology/UW	1987 - 1992

Ph.D. Thesis Committee - continued

Mr. Steven Chessler	Pathology/UW	1989 - 1992
Ms. Elizabeth Ann Everitt	Biological Structure/UW	1989 - 1992
Mr. Timothy Scranton	Biophysics and Physiology/UW	1991 - 1995
Mr. Terry LaBell	Pathology/UW	1991 - 1995
Ms. Janice Benson	Biological Structure/UW	1992 - 1995
Mr. Larry Chun	Biological Structure/UW	1991 - 1995
Ms. Beth Kaplan	Biological Structure (Chair) /UW	1992 - 1996
Mr. James Pace	Pathology/UW	1997 - 2001
Ms. Michel Gooden	Biological Structure/UW	1998 - 2000
Ms. Joell Solan	Pathobiology/UW	1999 - 2002
Ms. Gabriella Curinga	Pathology/UW	2000 - 2004
Mr. Paul Keire	Pathology (Chairman)/UW	2001 - present
Mr. David Wu	Pathobiology, Univ. of Toronto (External Examiner)	2003
Mr. Kin Chan	Molecular & Cellular Biology/UW	2003 - present
Ms. Karin Tran-Lundmark	Vascular Surgery/Karolinska Institute Sweden (Co-supervisor – external)	2003 - present
Ms. Ingrid Harten	Pathology (Chairman)/UW	2004 - present
Mr. Thomas Robey	Bioengineering/Pathology/UW	2004 - 2007
Ms. JoSette Broiles	Bioengineering/Georgia Tech University	2003 - 2007
Ms. Ildiko Erdelyi	Pathology/University of Utrecht, The Netherlands (Co-Chair)	2004 - 2005
Mr. David Allison	Bioengineering/Rice University	2006 - present

Master of Science Thesis Committee

Mr. Michael McNutt	Pathology/UW	1983 - 1985
Mr. Ray Esclamado	Otolaryngology/UW	1984 - 1984
Mr. Ed Ricciardelli	Otolaryngology/UW	1986 - 1988
Mr. Andrew Nelson	Pathology/UW	1979 - 1985
Mr. Daniel Harrah	Pathology (Chairman)/UW	1983 - 1989

Medical Student Summer Research Training or Undergraduate Research Training

Mr. Jeff Stickney	UW	1983
Mr. Darren Hollenbaum	UW	1986
Mr. Scott Isenath	UW	1999
Ms. Rebecca Zuanich	UW	2001

Visiting Student Research Training

Daniel Hernandez	University of Barcelona, Spain	2005
Melanie Ivey	Baker Institute, Monash University, Australia	2005
Ildiko Erdelyi	Utrecht University, The Netherlands	2004
Kiet Tran	Karolinska University, Sweden	1998 - 1999, 2004
Karin Lundmark	Karolinska University, Sweden	1999, 2004
Stephanie de Dios	Monash University, Melbourne, Australia	2001

Visiting Student Research Training - continued

Montse Serra Muxi	Universitat Autonoma de Barcelona, Spain	2001
Julie Nigro	Monash University, Melbourne, Australia	2002
Robert Huang	University of Auckland, Auckland, New Zealand	2003

Post-Doctoral Fellows	**Present Position**
David Hajjar, Ph.D. 1977 - 1978	Professor of Pathology & Laboratory Medicine Professor of Biochemistry Dean of Graduate School Weill Medical College, Cornell University Cornell, NY
Michael Kinsella, Ph.D. 1980 - 1982	Research Associate Member Benaroya Research Institute Associate Professor of Pathology (Affiliate) University of Washington School of Medicine Seattle, WA
Renato Iozzo, M.D. 1982 - 1986	Professor of Pathology Director, Extracellular Matrix Program Thomas Jefferson Medical School Philadelphia, PA
Sandra Harris-Hooker, Ph.D. 1981 - 1983	Professor, Department of Pathology Associate Dean, Research Development Morehouse School of Medicine Atlanta, GA
Eileen Bryant, Ph.D. 1984 - 1986	Director, Cytogenetics Laboratory Fred Hutchinson Cancer Research Center Seattle, WA
Sarah Bingel, D.V.M., Ph.D. 1984 - 1986	Associate Professor Division of Laboratory Animal Resources Medical University of South Carolina Charleston, SC
Michael Lark, Ph.D. 1985 - 1987	Sr. Director of Cardiovascular & Metabolic Diseases Centocor Malvern, PA
Tet-Kin Yeo, Ph.D. 1987 - 1989	Research Assistant Professor Department of Medicine (Clinical Pharmacology) Dartmouth Medical School Lebanon, NH

Post-Doctoral Fellows - continued	**Present Position**
Alan Snow, Ph.D. 1988 - 1991	President & CSO Proteotech, Inc. Redmond, WA
Sandra Juul, M.D. 1990 - 1992	Associate Professor Department of Pediatrics University of Washington Seattle, WA
Elke Schönherr, M.D., Ph.D. (deceased) 1990 - 1993	Associate Professor University of Wales Cardiff, Wales
Hannu Järveläinen, M.D., Ph.D. 1990 - 1993	Associate Professor University of Turku School of Medicine Turku, Finland
Seppo Nikkari, M.D., Ph.D. 1992 - 1994 (shared)	Professor Department of Medical Biochemistry University of Tampere Finland
Luiz Cardoso, Ph.D. 1995 - 1997	Scientist University of Rio de Janiero Brazil
Stephen Evanko, Ph.D. 1996 - 1999	Staff Scientist Benaroya Research Institute Seattle, WA
Mary Chang, Ph.D. 1996 - 1998 (shared)	Research Assistant Professor Metabolism, Endocrinology & Nutrition Department of Medicine University of Washington Seattle, WA
Joan Lemire, Ph.D. 1994 - 1997	Research Assistant Professor Department of Anatomy and Cellular Biology Tufts University School of Medicine Boston, MA
Katherine Olin, Ph.D. 1998 - 2002 (shared)	Staff Scientist Zymogenetics Seattle, WA

Post-Doctoral Fellows - continued	**Present Position**
Lisa Tannock, M.D. 1999 - 2003 (shared)	Assistant Professor Cardiovascular Research Center Department of Medicine University of Kentucky Louisville, Kentucky
Pamela Johnson, Ph.D. 1997 - 2002	Staff Scientist Benaroya Research Institute Seattle, Washington
Tom Wilkinson, Ph.D. 2001 - 2004	Research Fellow University of Edinburgh Centre for Inflammation Research Edinburgh, Scotland
Sana Sakr, Ph.D. 2001 - 2005	Research Scientist Surgery University of Washington Harborview Medical Center Seattle, Washington
Rebecca Hull, Ph.D. 2001 - present (shared)	Research Assistant Professor Metabolism, Endocrinology, & Nutrition Department of Medicine VA Puget Sound Health Care System & University of Washington Seattle, Washington
Marsha Rolle, Ph.D. 2004 - 2007	Assistant Professor Biomedical Engineering Worcester Polytechnic Institute Worcester, MA
Masanari Obika, M.D. 2007 - present	Post-Doctoral Fellow Benaroya Research Institute Seattle, WA

Visiting Scientists	**Present Position**
Kuofen Chen, M.D. 1982 - 1983	Professor of Cardiology (Retired) Fu Wai Hospital Beijing, China

Visiting Scientists - continued

Bertram Levy, M.D. 1989 - 1990	Practicing Urologist Port Townsend, WA Affiliate Professor of Urology University of Washington School of Medicine Seattle, WA
Jens Fischer, Ph.D. 1996 - 1999	Professor Department of Molecular Pharmacology University of Dusseldorf Dusseldorf, Germany
Merv Merrilees, Ph.D. 1998 - 1999 2006	Associate Professor Department of Anatomy University of Auckland Auckland, New Zealand
Toshiyuki Kaji, Ph.D. 1998	Associate Professor Department of Pharmaceutical Sciences Hokuriku University Kanazawa, Japan
Robert Hurst, Ph.D. 1999	Professor Department of Urology University of Oklahoma Oklahoma City, OK
Hannu Järveläinen, M.D., Ph.D. 2000 - 2001	Associate Professor Department. of Medicine & Medical Biochemistry School of Medicine University of Turku Turku, Finland
Jin-Yong Hwang, M.D. 2001 - 2002	Assistant Professor Department of Internal Medicine Gyeoung-Sang National University Hospital and College of Medicine Jinju, Korea
Yann Gouëffic, M.D. 2002 - 2003	Assistant Professor Department of Vascular Surgery University Hospital of Nantes France

Visiting Scientists - continued

Peter Little, Ph.D. 2002	Head, Cell Biology of Diabetes Laboratory Baker Medical Research Institute Melbourne, Victoria Australia

PAST RESEARCH AWARDS

Year/s	Title (Role on Grant)	Annual Direct Costs
1978 - 1979	Basil O'Connor Starter Research Grant March of Dimes (PI)	14,165
1979 - 1981	March of Dimes Basic Research Grant (PI)	22,000
1980 - 1982	NIH - NHLBI Vasoactive Agents PI: Gary Striker (Co Investigator)	74,283
1979 - 1981	Sea Grant Carrageenan Effects (PI)	19,600
1981 - 1983	RO1: Endothelial Injury PI: Alexander Clowes (Co-PI)	72,000
1979 - 1985	Reynolds Industries Program PI: Russell Ross (Subproject PI)	22,070
1980 - 1985	NHLBI Program Project PI: R. Ross (Subproject PI)	68,000
1981 - 1986	AHA Established Investigator Award (PI)	30,000
1981 - 1985	AHA Grant In Aid (PI)	33,000
1982 - 1985	NHLBI RO1 Grant PI: Russell Ross (Co PI)	80,841
1982 - 1984	Poncin Award (PI)	3,600
1983 - 1985	NIADDK: RO1 Proteoglycans in Chondrodystrophy (PI)	71,000
1986 - 1987	Reynolds Industries Program PI: Russell Ross (Subproject PI)	36,930
1985 - 1991	NHLBI Program Project PI: Russell Ross (Subproject PI)	132,548

PAST RESEARCH AWARDS - Continued

Year/s	Title (Role on Grant)	Annual Direct Costs
1985 - 1991	NHLBI Program Project PI: Russell Ross (Core PI)	79,298
1986 - 1991	NIH Program Project in Dermatology PI: George Odland (Subproject PI)	81,277
1987 - 1992	Research Center in Oral Biology PI: R. Page (Subproject PI)	124,320
1987 - 1988	Alzheimer's Disease Research Center Pilot Project: University of Washington PI: George Martin (Subproject PI)	5,000
1987 - 1988	Alzheimer's Disease and Related Disorders, Inc. (Pilot Project PI)	20,000
1988 - 1990	American Health Association Alzheimer's Disease PI: A. Snow (Co-PI)	50,000
1990 - 1995	NIH Program Project - Biology of the Artery Wall PI: Russell Ross (PI: Project 7)	186,017
1990 - 1995	NIH Program Project - Biology of the Artery Wall PI: Russell Ross (PI: Morphology Core)	112,645
1990 - 1995	Alzheimer's Disease Research PI: A. Snow (Co-PI)	120,741
1992 - 1996	NIH (RO1) IL-1 and Matrix Signaling PI: Eva Qwarnström (Co-Investigator)	90,480
1994 - 1996	Bayer AG: Lipoprotein Matrix Interactions (Co-PI)	250,000
1994 - 1997	NIH (RO1): Air Pollutant Effects on Mediators in Lung Cells PI: D. Luchtel (Co-Investigator)	179,000
1996 - 1999	NIH (RO1) Mechanism of Matrix IL-1 Signaling (PI)	105,109
1995 - 2000	NIH Program Project (R. Ross, PI) Proteoglycans, Glycosaminoglycans and Atheroclerosis (PI: Project 7)	176,617

PAST RESEARCH AWARDS - Continued

Year/s	Title (Role on Grant)	Annual Direct Costs
1999 - 2000	Merck Industries: The effect of LTD4 and montelukast on extracellular matrix production by cultured airway cells (Co-Investigator)	50,000
2001 - 2002	Research Servier: Proteoglycans in Human Varicose Veins (PI)	100,583
2001 - 2002	Abbott Laboratories: Prevention of Aneurysms by Proteoglycan Gene Transfer (PI)	100,000
2002	GlaxoSmithKline: Effect of Fluticasone and Salmeterol on the Synthesis of Proteoglycans by Airway Smooth Muscle Cells (PI)	39,015
2003 - 2004	NIH Program Project (A. Chair, PI) Lipoprotein – Matrix Interaction in Diabetes "Pathobiology of Macrovascular Disease in Diabetes" (Co-Investigator)	107,790
1999 - 2004	NIH Lipoprotein Lipase Program Project (J. Albers, PI) "Lipoprotein Retention by Artery Wall Biglycan" (Co-Investigator)	22,858
2002 - 2004	GlaxoSmithKline: The Provisional Extracellular Matrix in Asthma: Possible Targets for Therapeutic Intervention (PI)	161,948
2000 - 2005	"Proteoglycans, Glycosaminoglycans and Atherosclerosis" NIH Program Project (John Harlan, PI) (PI: Project 7)	231,416
2002 - 2005	"The Use of Proteoglycan Genes to Engineer Vascular Tissue" NIH /HLBI Grant (PI)	154,715
2004 - 2005	National Science Foundation Engineering Research Center UWEB Sub Project, (B. Ratner, PI) "Construction of a Tissue Engineered Blood Vessel Using a Gene Therapy Approach" (PI)	61,758
2002 - 2007	Pathobiology of Macrovascular Disease in Diabetes NIH / NIDDK Program Project (A. Chait, PI) "Lipoprotein - Matrix Interactions in Diabetes" Project 1, Co-Investigator	62,850

2007 - 2008	Lung Extracellular Matrix (ECM) in Asthma: Alterations in Response to the R,R and S,S- Enantiomers of Formoterol Sepracor (T. Wight, Co-PI)	33,333
2007 - 2008	Pancreatic Islet Extracellular Matrix in Autoimmune Disease Cooperative Study Group for Autoimmune Disease Prevention (T. Wight, Project PI)	50,000